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1. INTRODUCTION 
  
1.1 Chemical modification of proteins 
 
In the last decades, owing to the improved understanding of biological 
processes and to the development of innovative chemical techniques, a new 
science field at the interface between biology and chemistry has emerged. 
This novel and expanding research area has the aim to investigate biological 
processes through a chemical approach via innovative bioconjugation 
techniques, a set of methods capable of site-specifically creating a covalent 
link between a biomolecule and a small molecule, a polymer or another 
biomolecule1,2. The importance of such modifications can be easily 
understood by observing any natural biochemical reaction. Chemical 
modification of proteins is a key step in most biological processes, is 
common in all cellular events and has the aim to alter and modulate protein 
structure and function. Examples of post-translational modifications (PTMs), 
chemical alterations taking place following the ribosomal synthesis, include 
amino acid phosphorylation, acetylation, methylation, formylation, 
glycosylation, hydroxylation, ubiquitination, etc3,4. The improved 
understanding of these in vivo modifications has opened the possibility to 
mimic and possibly expand nature’s ability in vitro, disclosing a vast area of 
ongoing research. Since its discovery, chemical modification of proteins has 
been used for a variety of purposes: from the design of novel protein based 
therapeutics5 to the improvement of their pharmacokinetic and 
pharmacodynamic properties6, from the introduction of fluorescent tags for 
cell imaging7 to the employment of radionuclides8 and to FRET-based 
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structural studies9, from the creation of new affinity tags to the 
immobilization of proteins10, etc.  
 
1.1.1 Selective chemical modification of proteins 
 
Nature’s selectivity in chemical modification is not always an easy task to 
reproduce in the laboratory. Poor control over the reaction often results in 
therapeutic conjugates with loss of their biological function11. Consequently, 
the biggest challenge in the field is the selective and controlled labelling of 
only one amino acid among a sea of many others. However, in order to site-
selectively modify a protein, many requirements need to be fulfilled. The 
chosen amino acid has to be accessible, exposed to the solvent, in order to 
react quickly and to be targeted in preference to the other amino acids around 
it. The reaction has to be biocompatible with the fragile nature of the protein 
to ensure its stability and the retention of its activity. Thus, the temperature 
has to remain under 37 °C, the pH has to be neutral and the reaction has to 
take place in an aqueous media with a minimum amount of organic solvents 
and in the presence of salts and surfactants that are often needed for protein’s 
stability. In addition, high concentrations of reactant must be avoided not to 
waste precious starting material and not to induce cell stress2,12,13. All these 
combined requirements strongly hinder the development of new methods but, 
despite the numerous challenges, after decades of research, a good variety of 
bioconjugation techniques is now available. Selectivity is commonly 
achieved via two main strategies: either the reaction is carefully tuned to be 
selective for a single natural amino acid or an unnatural amino acid with 
unique reactivity is incorporated into the protein of interest. This latter 
method inserts moieties such as amino acid analogues with a peculiar side 
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chain that will solely react with the labelling reagent14. The first method, 
instead, focuses on the labelling of the 20 available natural amino acids that 
are, therefore, immediately accessible without the need of additional 
modifications or specific techniques. Among the 20 natural amino acids only 
a few can actually be the target of bioconjugation techniques, and are the 
ones that present an intrinsic reactivity, often a nucleophilic site that can be 
modified with an electrophilic reagent. To this end, the methodology used is 
selected accordingly to the intrinsic reactivity of the targeted amino acid 
residue, depending on its acidity/basicity, electrophilicity/nucleophilicity, 
redox characteristics and its peculiar environment and hydrophobicity13. In 
this context, the reactivity of most hydrophilic residues has been exploited, 
and suitable reagents for selective protein modification have been developed 
for residues such as arginine15,16, aspartic acid17, cysteine2,18, glutamic acid19, 
histidine20, lysine21, tyrosine22. Among these reactions, the most exploited 
modifications have been on cysteine and lysine residues. This success is a 
consequence of the high nucleophilicity of their side chains, which can offer 
higher selectivity and reactivity compared to others amino acids. Only a 
selection of the most common chemical modifications will be discussed 
below as this dissertation has not the aim of developing new bioconjugation 
techniques but rather the aim to use these techniques in order to test 
hypothesis, develop versatile nanodevices and exploit them from a 
biochemical point of view. Nonetheless, in order to control and correctly use 
bioconjugation reactions, a profound understanding of the chemistry of 
protein modification is required.  
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1.1.2 Lysine modification 
 
Lysine is an amino acid bearing a primary amine on its side chain, which is 
commonly protonated under physiological pH, although it acts as strong 
nucleophile when deprotonated. The most common lysine labelling 
techniques, as shown in Scheme 1, include acylation with anhydrides23 (a), 
acylation with activated esters like N-Hydroxysuccinimide (NHS) esters 24 
(b), acylation with isothiocyanates25 (c) and reductive amination of 
aldehydes26,27 (d). A common drawback of this set of reagents is the alkaline 
pH, usually higher than 8, commonly required to approach the pKa of the 
lysine residue (pKa 10.5428) and necessary to provide a significant amount of 
deprotonated amino groups.  
 
 
  
Scheme 1: Lysine modification with a) anhydride, b) NHS ester, c) isothiocyanate  
and d) aldehyde12 
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NHS ester, the most reactive and widely used lysine modification reagent, 
has limited storage stability and must be often used in large excess due to its 
moisture sensitivity, thus increasing the chances of unselective reactivity with 
other amino acids29. An additional major disadvantage is the high abundance 
of lysine residues on protein surfaces that always gives a statistical mixture of 
heterogeneous reaction products12. A high number of modifications can rise 
problems such as product stability, due to the surface charge loss, which can 
increase the clearance rate from the patient blood, or as altered activity due to 
labelled lysines in or near the protein binding site30. Consequently, although 
lysine modification has been extensively used and many chemically modified 
biological products available bare a lysine modification, lysine labelling is 
not considered ideal nowadays.   
  
1.1.3 Cysteine modification 
 
Among the 20 natural amino acids, cysteine is the most exploited residue for 
site-selective protein modification due to its numerous advantages. Cysteine 
has a low natural abundance among proteins, ranging between 2.26 % in 
mammals and 0.5 % in some members of the Archaea bacteria order31 and, 
furthermore, it is also the most nucleophilic amino acid. These characteristics 
make cysteine an ideal residue for targeted site-selective modification of a 
few and controlled sites, avoiding unwanted side reactions and heterogeneous 
products. In addition, single cysteine residues can be site-selectively 
introduced via mutagenesis thus expanding the application field32 or, 
alternatively, native disulfide bonds can be reduced in order to exploit the 
thiolate reactivity for subsequent modification33. The high nucleophilic 
nature of cysteine is due to its sulfhydryl side chain, which has a pKa of 
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8.3728 and allows the residue to be present as a partially deprotonated thiolate 
at neutral pH, while the lysine’s amine will be mostly protonated. Thus, by 
carefully controlling the buffer pH, the nucleophilic character of the residue 
can be subtly tuned and, together with the accurate choice of the electrophilic 
nature of the reactive probe, preferential reactivity can be achieved. For these 
numerous reasons, cysteine labelling has been widely investigated and 
exploited and it will be further employed in this thesis, proving once again its 
versatility and site-selective reactivity.  
 
 
 
 
A selection of the most common chemical cysteine modifications is displayed 
in Scheme 2 and briefly explained below.  
 
 
Scheme 2: Cysteine modification with a) maleimide, b) NGM, c) -halocarbonyl 
 and d) disulfide12 
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 1.1.3.1 Maleimides 
 
Maleimides (maleic acid imides) are the most widely employed electrophiles 
for cysteine modification and were first introduced by Friedmann in 1949 as 
the product of the reaction between maleic anhydride and amine 
derivatives13,34. Maleimide is an α,β-unsaturated 5-member ring, containing 
an imide group in which the two carbonyls are conjugated with the C=C 
double bond. The reagent acts as the Michael acceptor in a Michael addition 
reaction with the cysteine thiolate, forming a thiosuccinimmide as reaction 
product as shown in Scheme 3.  
 
 
The strong electrophilic nature of maleimides is the key to the great success 
of these compounds in the bioconjugation field and is mainly ascribable to 
two features. The first is the fact that the molecule bears electron 
withdrawing groups (EWG) that lower the energy of the lowest unoccupied 
molecular orbital (LUMO), while the second is the straining of the double 
bond that decreases the energetic gap between the highest occupied 
molecular orbital (HOMO) and the LUMO. Both of these effects contribute 
to the decrease of the LUMO energy of the alkene and, consequently, to the 
increase of the compound reactivity13. Maleimides, therefore, offer rapid 
reactions under physiological conditions, giving conjugation products in 
Scheme 3: Schematic mechanism of a Michael addition reaction between  
thiol and maleimide 
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nearly quantitative yields without the need for a large molar excess of 
reagent, thus being widely applicable to several conditions and biological 
molecules.  
Despite the numerous advantages, maleimides have also some limitations that 
must be considered in order to properly use these reagents. The biggest 
restraint is their susceptibility to undergo spontaneous hydrolysis in aqueous 
buffers at pH above 8 either making the compound unreactive towards thiols 
or, if already conjugated, affording a mixture of isomeric succinamic acid 
adducts by ring-opening11,13,35. Temperature, pH and the presence of electron 
withdrawing substituents strongly influence hydrolysis rates. A linear 
relationship between pH and hydrolysis rate was found, reducing the half-life 
of maleimides from 42 h at 30 °C and pH 7 to less than 24 h at pH 8.536, 
while Fontaine et al.37 studied the ring-opening acceleration by electron 
withdrawing N-substituents introduction. Additionally, if a reactive lysine is 
proximal to the cysteine-maleimide conjugate, crosslinked products can be 
formed by nucleophilic attack of the primary amine onto the maleimide imide 
moiety thus irreversibly opening the ring in a process called aminolysis38,39. 
A third issue, which has emerged only over time, is the maleimide leaking 
witnessed especially in strongly reducing environments, even though the 
reaction was at first thought to be irreversible. As a matter of fact, the 
conjugation product was found to be susceptible to a retro-Michael reaction 
in which the maleimide ring is released and is able to subsequently react with 
other thiols in the environment, thus potentially realising toxic drugs or 
probes before reaching their target13,40. Nevertheless, these numerous issues, 
once investigated and understood, could also turn out to be an advantageous 
resource for linker stability tuning and controlled drug release, and indeed 
several research groups have explored these opportunities30,40. For instance, 
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hydrolysis or aminolysis could both promote the ring opening thereby 
preventing a retro-Michael reaction and increasing the stability and 
therapeutic activity of the conjugate30,41. Deliberate acceleration of the ring-
opening hydrolysis reaction can be catalysed by incorporation of basic 
functional groups adjacent to the thiol-maleimide conjugate to afford a stable 
product30, or by designing the maleimide N-substituent in order to favour 
basic catalysed hydrolysis41,42. On the other hand, the Michael reaction 
reversibility, could also be exploited for controlled delivery, for instance in 
reducing environments such as cell cytoplasm, where the glutathione 
concentrations can reach approximately 10 mM thus favouring the 
consequent drug release43. In conclusion, these issues do not diminish 
maleimide importance in the bioconjugation field, but instead this class of 
compounds has shown to be a complex and versatile platform.  
 
1.1.3.2 Next generation maleimides  
 
Recently a new class of maleimide derivatives, called next generation 
maleimides (NGMs), has been introduced by Baker et al. expanding the 
abilities of this set of reagents44,45. NGMs are maleimides that can be 
substituted either in only the 3- position or both in the 3- and 4- positions 
with two good leaving groups, such as bromines, named mono-bromo and di-
bromo maleimide respectively. The incorporation of a leaving group enables 
an addition-elimination reaction sequence with a first thiolate addition on the 
maleimide double bond, following the subsequent elimination of the bromide 
forming a thiomaleimide, with the retained double bond, as the product. If a 
second leaving group is present, the reaction sequence can be repeated a 
second time, always yielding a thiomaleimide product which, in contrast to 
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the saturated thiosuccinimide product obtained in a thiol-maleimide reaction, 
can further react. In total, di-bromo maleimides can offer three points of 
attachment or, otherwise, can be used for reversible cysteine modification as 
the thiomaleimide conjugate is cleaved by TCEP treatment44. But, above all, 
their major interest is in the capability of re-bridging reduced disulfide bonds 
by a 2-carbon bridge insertion which does not alter protein stability and 
structure, whilst functionalising the protein and retaining the cleavable ability 
in reducing environments by an addition-elimination mechanism33,46. These 
reactions are fast, efficient, high yielding and generate robust products that 
can either release their cargo in reducing environments such as cell cytoplasm 
or be “locked” by hydrolysis in a highly homogeneous and stable conjugate 
with retained biological activity42. 
 
1.1.3.3 α-Halocarbonyls  
 
Alkylation of cysteine is an alternative common reaction that exploits α-
halocarbonyls such as iodoacetamides or chloroacetamides in a SN2 
(nucleophilic substitution 2) reaction in which the α-halocarbonyl acts as the 
electrophile and the cysteine thiolate acts as the nucleophile that displaces the 
halogen atom forming a stable covalent bond. Although the use of 
maleimides is often preferred because of their higher reaction rates, α-
halocarbonyls represent a valid alternative especially in applications where 
the stability of the product is crucial13. The reaction is commonly carried out 
under slightly basic conditions, at pH between 8 and 9, to generate a fast 
reaction and avoid iodoacetamide undesired reactions with other nucleophilic 
side chains, especially common when a high excess of reagent is required. 
Cross reactivity can also be eluded using the less reactive chloroacetamides, 
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which exhibit a greater specificity due to their slower reaction rate and 
diminished electrophilic nature. In addition, chloroacetamides are also 
preferred over the iodoacetamides to limit free iodine generation, a reagent 
capable of reaction with residues such as tyrosine, histidine or 
triptophane.13,47 
  
1.1.3.4 Disulfides  
 
Cysteine oxidation is a reaction often exploited by nature to create disulfide 
bonds to stabilize the tertiary and quaternary protein assembly and is, 
therefore, a crucial reaction in post-translational modifications and protein 
folding3. Inspired by nature, scientists have also extensively exploited thiol-
disulfide exchange reactions for cysteine modification, a reversible reaction 
in which a cysteine thiolate breaks a disulfide bond attacking one of the 
sulphur atoms, releasing a new thiolate and forming a new mixed disulfide 
bond. The reaction is highly selective and can be carried out in mild 
conditions but, unfortunately, due to its reversible nature, it is susceptible to 
thiols and reducing agents and this aspect strongly limits its application. The 
most important example of thiol-disulfide exchange reaction is the Ellman’s 
assay reaction, used to quantify free reduced thiols in solution, exploiting the 
so-called Ellman’s reagent (5,5dithiobis(2-nitrobenzoicacid) or DTNB) 
properties48. The TNB (2-nitro-5-thiobenzoate) is an optimal leaving group, 
with the ability to shift the equilibrium toward the mixed disulfide product 
and, in addition, its formation can be monitored by UV-Vis spectroscopy 
thanks to TNB distinct absorption at 412 nm49,50. However, if the thiol-
disulfide exchange equilibrium can not be strongly shifted toward a preferred 
product, labelling with non activated-disulfides can require a large reagent 
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molar excess, with the risk of unwanted side reactions. An ultimate issue in 
using this set of reagents in protein conjugation is the lack of control over the 
possible disulfide scrambling that can eventually bring to aggregation.   
 
1.2 Ferritins  
 
Ferritins have been first identified in 1894, in horse liver, by the 
pharmacologist O. Schmiedeberg and have been later isolated for the first 
time in 1937, from horse spleen, by V. Laufberger51,52. Since then, ferritins 
have been ubiquitously found in all life kingdoms, from bacteria and archaea 
to plants and animals, and have never failed to attract scientists’ interest for 
various purposes. Ferritins are large proteins of 480 kDa, composed of 24 
subunits that assemble together to form a highly symmetrical and spherical 
hollow cage (Figure 1A), with an external diameter of 12 nm and an internal 
one of 8 nm (Figure 1B). 
 
The building block subunits that participate in the ferritin structure self-
assembly are not always identical in ferritins of different species. While 
A 
 
B 
 
Figure 1: A) Ferritin structure in which each subunit is depicted in a different colour; 
 B) Schematic depiction of ferritin cavity dimensions 
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plants and bacterial ferritins are homopolymers, mammalian ferritins are 
made of two different kinds of subunits: heavy (H) and light (L) of 21 and 19 
kDa respectively in human ferritin.  
Ferritins are biologically designed to oxidise and store iron within their 
cavity, accommodating up to 4500 atoms as a microcrystalline hydrated 
ferric oxide named ferrihydrite. Despite a significant effort to define the 
events that take place during the catalytic cycle, the mechanism is still not 
fully understood53. However, even though there are many contrasting 
indications, the majority of the studies agree that the iron atoms enter through 
eight hydrophilic channels, about 4-6 Å in diameter, located at the 3-fold 
symmetry axis, thanks to an electrostatic gradient generated by the negative 
electrostatic potential of the three-fold channels and the ferroxidase sites 
together with the positive electrostatic potential of the 3-fold channel 
surrounding regions, which can guide the cations inside the cavity toward the 
ferroxidase centre54. One catalytic centre has been identified in the middle of 
each ferritin subunit and is made of three distinct metal binding sites, except 
for L subunit which lacks ferroxidase activity and serves as nucleation and 
mineralization site55. Among the three ferroxidase centre sites, two sites, 
called A and B, are located in the middle of each subunit while a third metal 
binding site is just a bit further and closer to the inner ferritin surface (Figure 
2). The third site C, does not have a catalytic activity, but might be involved 
in the nucleation process53. Each iron atom in the ferroxidase centre is five-
coordinated. In site A, the site with the strongest iron affinity, the metal 
coordinates three oxygen atoms, one nitrogen atom and a water molecule. 
Four oxygen atoms and a water molecule coordinate the metal in site B. 
Amino acids in the ferroxidase centres are highly conserved among the 
different species and include glutamates, glutamines and histidines53. When 
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ferritins are loaded with iron, they are commonly addressed as ferritins, or 
holo-ferritin, while a cage empty ferritin, with no iron in its cavity, is 
addressed as apo-ferritin. 
 
Living organisms have developed this peculiar protein machine, not only to 
store iron, but also to protect themselves from free circulating iron cations, 
which can form free radicals by reaction with reactive oxygen species (ROS), 
and ultimately cause oxidative stress and cell damage53. Despite the main 
iron-storage and antioxidant functions, recent studies are underlying the 
importance of ferritin’s involvement in many other biological roles56 such as 
inflammation, cancer57, immunity and autoimmunity58, Parkinson’s and 
Alzheimer’s diseases59,60.  
 
  
Figure 2: Ferroxidase centre from Pyrococcus furiosus (PDB 2X17) in which the A, B and 
C sites are presented as green spheres and the residues involved in iron coordination are 
highlighted in cyan  
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1.2.1 Ferritin uptake 
 
Ferritin has been located into the blood stream and in multiple cell 
compartments, from the cytosol to the nucleus, as it can easily bind and enter 
into a variety of cell types. Unfortunately, despite the long time spent on 
ferritin studies, only recently, a few ferritin receptors have been identified. 
The most important ferritin receptor, the transferrin receptor-1 (TfR1, also 
known as CD71), has been known for a long time as the transferrin receptor, 
but only recently, in 2010, it has been recognised also as the H-ferritin 
receptor61. This newly discovered TfR1 dual function underlines the 
important role of this receptor in iron homeostasis. TfR1 is a dimeric 
transmembrane receptor composed of two 95 kDa subunits, linked by 
multiple disulphide bonds. Each subunit presents a short cytoplasmic domain, 
a hydrophobic transmembrane domain and a large extracellular domain62,63. 
While the binding site of transferrin is known to be located in the 
cytoplasmic lobe, the ferritin binding site hasn’t been yet identified, but 
ferritin’s binding behaviour has been deeply investigated and interesting 
evidences have emerged. For instance, it is evident that TfR1 can specifically 
bind only H-ferritin polymers while it lacks any affinity for the L-polymers. 
In addition, the H-ferritin binding is only partially inhibited by transferrin 
treatment, suggesting the possibility that two distinct binding sites might 
exist for ferritin and transferrin61. It has also been demonstrated, by blocking 
the TfR1 receptor with a specific monoclonal antibody, that most of ferritin’s 
uptake is actually regulated by TfR1 in many cells such as B cells, T cells, 
reticulocytes, macrophages, etc., as the ferritin uptake has been almost 
completely inhibited61.  
Chapter 1: Introduction 
 
16 
 
After TfR1 binding the ferritin cellular internalization pathway shows a 
similar behaviour to that of transferrin, where the protein-receptor complex is 
uptaken by a clathrin mediated endocytosis process62,64,65. Clathrin mediated 
endocytosis is a common internalization pathway composed of several steps. 
At first, the cell membrane slowly forms a vesicle around the receptor-protein 
complex, trapping both the ligand and the receptor within the vesicle cavity. 
Then, the vesicle is completely covered by clathrin molecules and delivers 
the protein ligand to its fate. Finally, the receptor is either recycled or 
degraded into the lysosomes65. 
A confocal microscopy study on ferritin internalization into HeLa cells by 
Bellini et al.66 has shown that ferritin quickly interacts with the TfR1 on the 
cell membrane within 15 minutes, and is later completely internalized within 
3 hours of incubation. By marking different endocytic compartments with 
fluorescent tags, it has been demonstrated that ferritin is already localised in 
the early endosome after only one hour, thereafter never reaching either the 
Golgi apparatus, the recycling endosome or the lysosomes. Consequently, the 
fate of ferritins once inside the cell is still unknown, but these evidences 
suggest that the protein is not immediately degraded and thus can be 
exploited as a long lasting nanocarrier66. By investigating ferritin uptake in 
different kind of cells, a high ferritin internalization has been shown in 
several cancerous cells such as melanoma cells, breast cancer cells, 
erythroleukemia cells, HeLa cervical cancer cells, ovarian cancer cells, 
prostate cancer cells, glioblastoma cells, pancreatic cancer cells, etc.62,67. This 
effect is probably due to the increased iron requirements necessary for the 
rapid tumour growth. Indeed the TfR1 expression level in cancerous cells can 
be up to 100 times higher than in normal healthy cells. This discovery 
suggests that ferritins may actually find application in the treatment of 
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several tumours, as they will be selectively highly uptaken and accumulated 
into tumour cells, where they can eventually selectively release encapsulated 
chemotherapeutic drugs.  
Despite TfR1 is the most important ferritin receptor found up to now, the 
very first ferritin receptor discovered is TIM-2, the mouse T-cell 
immunoglobulin and mucin domain-2, a receptor overexpressed in mouse B-
cells68,69, kidneys68,69, liver69, oligodendrocytes70. The TIM-2 receptor has 
been located only in mice and no analogue has been found in humans, in the 
same way as no corresponding murine TfR1 receptor has ever been found in 
mice. However, similarly to TfR1, TIM-2 lacks affinity for L-ferritin61 and is 
internalized via a clathrin mediated endocytosis pathway that will bring the 
TIM-2 receptor either into the endosomes or into the lysosomes68.  
The third and last ferritin receptor identified is the Scavenger Receptor Class 
A Member 5, SCARA-571. This ferritin receptor is the first receptor identified 
that binds only the L-polymer, while it lacks any affinity for the H-polymer. 
SCARA-5, as well as the other known receptors, delivers ferritin inside the 
cell through the endocytic pathway and it has been found expressed in mouse 
liver, developing kidneys, bladder, lungs, trachea, retina, macrophages etc. 
but no orthologue has been found in humans yet57,71.  
To conclude, even if ferritins is usually considered a cytoplasmic protein, 
there have been reports locating H-ferritin into the nucleus of neurons, 
hepatocytes and cancer cells72. Bellini et al.66, for instance, describes the 
nuclear internalization of a doxorubicin loaded H-ferritin. The research group 
proposes that ferritin might be uptaken inside the nucleus in response to 
oxidative stress. The uptaken ferritin, indeed, thanks to its known antioxidant 
action, would have a DNA protecting role against oxidative damage. 
Unfortunately, the nuclear ferritin uptake mechanism is still unknown, but 
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recent evidences suggest that an active transport mechanism is involved, 
which however does not require any nuclear localization sequence66,72,73. In 
conclusion, ferritin nuclear uptake, if further explored and potentially 
controlled, could be an interesting feature for the development of nuclear 
selective drug delivery nanoplatforms.  
 
1.2.2 Ferritin structure and assembly  
 
All ferritin proteins display a highly conserved tertiary structure, in which 
each of the 24 subunits is composed of a four-helix bundle namely A, B, C, 
D, and a fifth additional short E helix at the C-terminus as shown in Figure 
3A. A solvent exposed and flexible loop connects helices B and C and is 
involved in the stabilization of the dimer interface, in which two antiparallel 
monomers are oriented head to tail with respect to each other as shown in 
Figure 3B. Each dimer has many extended contacts and interactions which 
are polar between the loops and apolar between the helices. 
 
 
Figure 3: A) Ferritin monomeric subunit, B) ferritin dimer interface, with the interacting 
BC loops highlighted in magenta     
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The 24 monomers commonly assemble with an octahedral 4-3-2 symmetry, 
in a packing that results in the formation of several channels. At the 3-fold 
symmetry axis (C3), a total of eight negatively charged hydrophilic channels, 
which commonly mediate the iron entrance into the protein cage, are formed, 
while, at the 4-fold symmetry axis (C4) there are six hydrophobic channels 
(Figure 4). In addition, a small channel at the junction of three monomers, 
named B pore, can be found along the interface that connects the C3 and the 
C4 axes as shown in Figure 474. In total, each dimeric unit interacts with four 
adjacent dimers, with three main kind of contacts: the C3, along the 3-fold 
axis, the C4, along the 4-fold axis, and the C3-C4, the interface that connects 
the two symmetry axes covering the largest interaction area (Figure 4)75. 
 
Figure 4: Depiction of the main ferritin subunit contacts and channels 
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Self-assembly of the 24 subunits is a spontaneous process driven by several 
non-covalent interactions including hydrogen bonding, hydrophobic and van 
der Waals interactions. Despite the single interactions are rather weak, the 
high amount of them synergistically create a highly stable quaternary 
structure76. Site-directed mutagenesis studies have been widely employed to 
investigate the role of specific residues in ferritin self-assembly. Amino acid 
removal from the C-terminal E-helix or from the N-terminal does not alter 
ferritin assembly but only influences the cage stability76,77. On the contrary, 
alterations of crucial contacts within the dimer interface or in the BC loop 
completely inhibit the self-assembly, providing only monomers incapable of 
any reciprocal interaction75,78. Mutagenesis at the 3-fold and 4-fold channels 
affects protein stability, while leaving the 24-meric assembly intact78. The 
understanding of these non-covalent interactions is essential in order to be 
able to externally control and manipulate the cage stability for 
biotechnological purposes.  
Although the assembly of ferritin is a complex and not already fully 
understood process, it has already been widely exploited for different 
purposes. In 1973, horse spleen apo-ferritin was for the first time 
disassembled at pH 1.6 and then reversibly reassembled by bringing the 
buffer pH back to neutrality79. Similarly, the protein cage can be 
disassembled by increasing the pH. Denaturants such as sodium dodecyl 
sulphate or guanidine hydrochloride, however, can only denature the protein, 
while treatment with 8 M urea does not alter the assembly state79. The 
thermodynamic and kinetic aspects of this curious pH-triggered self-
assembly behaviour have been studied during the 80’s by fluorescence80, CD 
spectroscopy81, sedimentation velocity centrifugation81, covalent cross-
linking with glutaraldehyde80, and more recently by SAXS82,83. 
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Unfortunately, the results of these studies are confusing and incomplete, as 
the self-assembly oligomerization process of a highly symmetrical and 
oligomeric protein is hard to characterize, due to the many possible 
intermediates and pathways that can take place during the reaction74. 
However, all these studies80–83, supported also by mutagenesis 
investigations75, seem to agree on the fact that the very first stable assembly 
building block is the dimer. In addition, the existence of a significant 
population of oligomeric intermediates has been proposed and include mainly 
trimers, tetramers, hexamers, octamers and dodecamers. In conclusion, it is 
possible to speculate that in an acidic environment the protein disassembles 
into dimeric units which then, once the buffer is brought back to neutrality, 
will start to associate into different kinds of oligomers that eventually will 
form the 24-meric cage-like protein.  
In recent years, the ferritin’s cage pH induced reversible 
association/dissociation process has been widely exploited to load larger 
probes or drugs within the protein’s cavity. The cage has been indeed 
disassembled in acidic conditions and reassembled by pH switch in a solution 
containing a high concentration of the selected cargo, in such a way that a 
high number of molecules would be statistically trapped inside the cage. 
These cargo-loaded ferritins have recently been employed for various 
biotechnological applications ranging from bioimaging to drug delivery. 
However, only recently, a SAXS study has demonstrated how this process is 
not entirely ideal and has instead some drawbacks83. The apo-ferritin cage is 
quite stable in the pH range 3.4-10 but, outside this range, the dissociated 
subunits do not always reassemble correctly when brought back to neutral 
pH, leaving holes on the cage structure, corresponding to missing dimers. 
This evidence suggests that at pH 2, the pH commonly employed in probe 
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encapsulation procedures into the ferritin cages, the protein is partially 
irreversibly denatured and therefore incapable of a completely reversible 
reassociation process83. Afterwards, in an effort to improve and control the 
unclean but still useful pH-triggered assembly/disassembly process, the 
protein cage has been willingly destabilised by removing amino acids from 
the C-terminal sequence76 or by adding a pH sensitive peptide84, in order to 
cause the disassembly at milder pH. The necessity to have a flawless, easy 
and completely reversible assembly mechanism is indeed highly important. 
To this end, thanks to the knowledge gained on the ferritin structure and 
assembly and the will to shape this structure accordingly to every possible 
necessity, researchers have been able to design and produce ferritins with 
unexpected shapes and properties such as an oval ferritin with 16 
monomers85 or a bigger cavity with 48 subunits86. In conclusion, the widely 
explored ferritin’s cage versatility and stability are the key ingredients that 
make this scaffold incredibly useful and resourceful for any imaginable 
biotechnological application. However, the thermodynamic and kinetic 
characterization of the reversible assembly/disassembly mechanism is an 
underestimated but even more important goal, as the success of the ferritin 
based drug delivery system relies on the effective design and control of the 
process.  
 
1.2.2.1 Archaeoglobus fulgidus ferritin structure and assembly 
 
One of the most peculiar ferritin structure is the one from the hyper-
thermophilic archaea Archaeoglobus fulgidus (AfFt)87. In AfFt the 24 
subunits, instead of the typical octahedral 4-3-2 symmetry, assemble with a 
tetrahedral 2-3 symmetry, causing the formation of four wide triangular pores 
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on the protein cage surface with a height of 45 Å as shown in Figure 5A. Up 
to date, this is the only ferritin found that presents such a unique assembly, as 
even other archaea ferritins show the typical octahedral symmetry.  
 
 
In this peculiar tetrahedral assembly, hexamers are the highest oligomers 
with extended interactions and four hexamers assemble to form the spherical 
cage-like protein with the characteristic holes (Figure 5B). The large pores 
may allow for entry of large molecules, especially if negatively charged, as 
along the pore apices there are cluster of positive surface potential that may 
attract anions. Despite these large pores, iron cations apparently always enter 
the internal cavity through the 3-fold channels88. The novel protein packing, 
indeed, leaves the 3-fold channels intact, even though there are only four C3 
channels instead of eight, but completely destroys the 4-fold channels that are 
no longer present on the AfFt structure.  
An additional unique feature of the AfFt protein is its ionic strength driven 
assembly. The ferritin is indeed present in its dimeric state in low ionic 
Figure 5: Archaeoglobus fulgidus ferritin structure with A) the typical triangular pore and 
B) the hexamers depicted with different colours  
A
 
 
 
 
 
  
B
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strength buffers (e.g. 20 mM NaCl), while it assembles into 24-mers only at 
high ionic strength (e.g. 500 mM NaCl), as demonstrated by gel filtration 
chromatography at increasing NaCl concentrations87,89. This effect is 
probably due to the extended hydrophobic interactions between dimers that 
are enhanced at high ionic strength, bringing the subunits closer together, 
forcing them to assemble into the 24-meric state, to minimize the solvent 
exposure87,88,90. Successively, Sana et al. have also described a successful 
attempt of iron-triggered self-assembly of the dimeric AfFt subunits88. In 
addition, the reversible dissociation process induced by dissolving the iron 
core with reducing agents has also been characterised. As the complete 
assembly is reached by addition of only 20 ferrous iron per subunit, Sana et 
al. has proposed an additional active role of iron binding to the ferroxidase 
centre in the stabilization of the inter-subunits interactions that eventually 
favours the self-assembly process88.  
Overall, this newly discovered archaea ferritin has unique features such as its 
peculiar pore structure, that can facilitate the entrance of cargos inside the 
ferritin’s cavity, and as its sodium- or iron- induced assembly, that offer a 
new set of association/dissociation molecular triggers, opening new 
possibilities for the encapsulation of molecular cargoes into a mild neutral 
environment. Indeed, with AfFt there is no need to reach extreme acid 
conditions that endanger the protein stability and limit the possibility of 
cargos encapsulation to only strong, stable and acid-resistant molecules. 
By analysing the AfFt amino acidic sequence and structure, Sana et al. 
located two critical non-conserved residues, Lys-150 and Arg-151, as 
probably involved in the protein’s unique assembly. The two positive 
residues, that are located at the big pore’s apices, might indeed create strong 
repulsive electrostatic interactions that destabilise the classical octahedral 
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assembly. With the aim of investigating the possible role of these two amino 
acids, an Archaeoglobus fulgidus mutant, where Lys-150 and Arg-151 are 
replaced by two hydrophobic alanine residues, has been designed, expressed, 
purified and crystallized. The substitutions, as expected, remove the repulsive 
destabilizing forces and, unexpectedly, the mutant’s assembly switches back 
to the typical octahedral one, with no pores, thus demonstrating the crucial 
involvement of the two residues. Surprisingly, the K150A-R151A AfFt 
mutant, despite the cage closure, has maintained intact the ability to assemble 
with increasing salt concentration, with a slightly higher preference for the 
assembled state at comparable ionic strength90.  
Overall the peculiar structural features of this archaea ferritin have opened 
new horizons for drug delivery and, at the same time, allow for an easy and 
controlled switch between two different cage architectures90. 
 
1.2.3 Ferritin in drug delivery and imaging 
 
In the last years, nanoparticles have displayed their great potential as versatile 
tools for many biotechnological applications spanning from nanoreactors and 
nanosensors to nanoplatforms for bioimaging and drug delivery. 
Nanoparticles have several advantages including dimensions and versatility, 
as they can acquire new functionalities by genetic engineering or chemical 
modification of their external surface, inner cavity or interface between the 
subunits. Usually, metals, drugs or any kind of probe are loaded inside the 
interior cavity, hidden from the outside, while the external surface is 
variously functionalised with the introduction of tags, fluorophores, peptides, 
antibodies or other moieties for selective targeting91.  
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Ferritin is an interesting and ideal nanoparticle for its numerous peculiar 
features. It has a regular, uniform and homogeneous shape that grants a 
narrow size distribution. Being an endogenous protein, it is biocompatible, 
soluble and stable in the blood stream, as well as biodegradable. It has the 
right size to avoid rapid clearance through kidneys while granting a long 
circulation half-life. From a synthetic point of view, it is easily produced as a 
recombinant protein in E. coli cells yielding high amounts ranging between 
100-200 mg l-1 of ferritin on a laboratory scale. Its stability to a wide range of 
temperatures and pH conditions facilitate its purification procedure, as 
unwanted E. coli endogenous proteins can be denatured and precipitated by 
heat shock and finally removed by simple centrifugation. This simple and 
clean production and purification protocol might also be ideal for a future 
easy and low-cost industrial scale-up. In addition, the protein has an intrinsic 
versatility and can be variously functionalised on the surface or in the inner 
cavity where the hollow cage can host hundreds of molecules. As each 
ferritin has 24 identical subunits, by genetic engineering of a single amino 
acid, 24 sites can be easily site-selectively introduced and customised thus 
easily amplifying the desired effect. At last, the most important feature is the 
already mentioned ability to be selectively uptaken by cancerous cells thanks 
to the higher expression level of the TfR1 receptor. These several crucial and 
remarkable features, all available in one unique device, make ferritin an 
amenable scaffold for the design of bioimaging and drug delivery 
nanoplatforms.  
Relevant examples of ferritins in the bioimaging field include their use in 
magnetic resonance imaging (MRI), fluorescence optical imaging or positron 
emission tomography (PET). For instance, the ferromagnetic iron oxide core 
trapped inside the cavity can be detected by MRI, a powerful diagnostic 
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technique with high sensitivity and accuracy used for tumour diagnosis92,93. 
Indeed this technique, exploiting ferritin iron core and ferritin uptake by 
cancerous cells, was able to detect micro-tumours at early stage in vivo in the 
brain, proving at the same time the ferritin’s ability to cross the blood brain 
barrier (BBB)94,95. In fluorescence optical imaging, instead, ferritins can 
either be conjugated on the external surface with fluorescent dyes or loaded 
with fluorescent rare earth atoms inside the cavity96, while the encapsulation 
with radioactive compounds is used to produce ferritins for positron emission 
tomography (PET)97. 
Regarding the drug delivery field, ferritins are exploited either for their 
ability to attract metal cations inside their cavity or for their reversible 
association/dissociation assembly induced by a pH switch, or by a ionic 
strength switch in the case of Archaeoglobus fulgidus ferritin. The first 
examples of encapsulation involved atoms such as silver98, gold89,99, 
uranium100, gadolinium101 and platinum derivative as cisplatino, carboplatino 
or oxaliplatin102–105. Following these first approaches, molecules with 
positive charges or with the ability to bind metals such as desferrioxamine 
B106, ferrocene107 or doxorubicin in complex with copper(II)108, have been 
encapsulated into the ferritin cavity. The complexation with metal cations 
provides a driving force that guide the passage of a molecule through the 3-
fold axis which, otherwise, would not be accessible. However, several studies 
reported the successful encapsulation of cation free doxorubicin into the 
ferritin’s cage by simple pH-triggered disassembly/assembly66,109–111. These 
protein complexes showed a minor cardiotoxicity compared to free 
doxorubicin, as well as a higher tumour uptake, a longer half-life, a 
diminished drug resistance and a stronger tumour inhibition.  
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Further encapsulation experiments of probes with no preferential affinity for 
the internal ferritin surface can be rather challenging, due to the limited 
interaction between the protein and the molecules. Any encapsulated probe 
with low or no affinity will slowly pass through the protein pores causing a 
potentially dangerous leak. Indeed, only a few lipophilic molecules have been 
encapsulated into the ferritin cage such as curcumin112, β-carotene113 and 
aminoantracene114. However, the molecules low hydrosolubility strongly 
affects the encapsulation yield and this is the reason why only a few studies 
have been published on the matter.  
Ultimately, the ability to offer a new approach to concomitant therapy by 
encapsulation of different drugs in the same cage, or the ability to create 
multifunctional nanodevices for both imaging and drug delivery97,111,115,116, 
has opened a new stimulating and promising field in which ferritins have a 
decisive role in the battle of many diseases with a particular regard for the 
tumour targeted delivery.  
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2. AIM 
 
Chemical modification of biological entities has widespread in the recent 
years leading to the creation of novel biochemical investigation approaches 
and innovative biological systems for therapeutic and diagnostic purposes. 
Among the novel nanoscaffolds for biotechnological application, ferritins 
have been gaining increasing attention due to their remarkable properties. 
Ferritin proteins are indeed stable, biocompatible, versatile, easily produced 
and modified, but most of all they present a unique uniform and homogenous 
spherical shape with an internal cavity of 8 nm diameter suitable for cargo 
loading and delivery. Most protocols for the encapsulation of large molecules 
in ferritin envisage, however, a controversial pH-induced 
assembly/disassembly of the ferritin cage that commonly involves drastic pH 
values (pH 2) which may be harmful to both the protein structure and the 
loaded cargo. The work presented in this thesis has thus the aim of exploiting 
chemical modification procedures to investigate the ferritin oligomerization 
process and the entrapment of endogenous molecules within the protein 
nanocage in a mild physiological environment.  
The Pyrococcus furiosus (PfFt) ferritin, a model for the human ferritin 
nanocage, has been engineered and chemically modified on the surface with 
an azobenzene moiety, a molecular photoswitch which, upon light-induced 
trans-cis isomerizations, can promote the opening and reclosure of the 
protein scaffold. The permeability of the canonical close PfFt 24-meric cage 
was compared with the unique Archaeoglobus fulgidus ferritin (AfFt), the 
only known ferritin cage displaying four wide triangular pores on the surface, 
by exploiting the thiol chemistry by means of a disulfide exchange reaction 
with Ellman’s reagent. Subsequently my thesis research work has focused on 
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the study of the peculiar AfFt oligomerization properties, which bring the 
protein into its associated state upon salt increase while dissociating it into 
dimers with chelating agents. AfFt has been chemically engineered by 
introducing two pyrene moieties on key cysteine residues at the protein dimer 
interface and the assembly process has been investigated thermodynamically 
and kinetically by observing the pyrene fluorescence changes upon 
oligomerization. Once the salt-induced assembly features were assessed, in 
order to exploit the AfFt architecture for in vitro applications in mammalian 
cells, a surface mutant (HumAfFt) with a “humanized” external loop 
mimicking the human ferritin recognition motif for the human ferritin 
receptor TfR1 has been designed and produced. A new pyrene-HumAfFt 
conjugate was synthesised and the pyrene fluorescence emission has been 
exploited to compare the oligomerization process with the AfFt mechanism 
and to follow HumAfFt uptake into human cancerous cells by TfR1 
recognition. At last, the HumAfFt mutant has been variously functionalised 
with different linkers and a small nucleic acid sequence with the aim of 
exploring the potential biotechnological application of this protein in drug 
delivery. 
Various chemical modifications techniques were further explored during a 
training semester at the University College of London where I studied 
different bioconjugation approaches for the improvement of new antibody-
drug conjugates (ADCs) which, however, were not discussed in the thesis but 
resulted in a publication (see Attachment 3).    
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3. MATERIALS AND METHODS 
 
3.1 Ferritin production and characterization 
 
3.1.1 Pyrococcus furiosus ferritin  
 
The gene encoding for Pyrococcus furiosus (PfFt) wild type ferritin was 
already available in our laboratory (PDB 2X17). Three different mutants 
were designed for different experiments but all with the aim of introducing 
cysteine residues within the protein amino acid sequence in site-specific 
positions. In the first variant PfFt P77C, a mutation on the solvent exposed 
protein surface was introduced, while in the PfFt G52C mutant, a cysteine 
residue was placed on the internal cavity surface. In the third mutant PfFt 
I124C/K135C, two different residues on the D helix were substituted by two 
cysteines. All these single point mutations were introduced in the wild type 
gene, cloned into the expression vector pET22b (Novagen), by using a PCR 
QuickChange Mutagenesis kit (Stratagene) with customised primers. The 
mutated plasmids were then transformed into E. coli TOP 10 cells and the 
resulting colonies were screened by DNA sequencing. The successfully 
mutated plasmids were transformed into BL21 (DE3) E. coli cells for further 
protein expression.  
All PfFt mutants were overexpressed and purified according to the same 
procedure. Each mutant was inoculated in 1 l of LB broth medium, 
containing 100 mg of ampicillin, with 5 ml of an overnight culture grown 
from one single colony. The overexpression was induced with 1 mM IPTG at 
an optical density at 600 nm (OD600) of 0.6 verified by UV-Vis spectroscopy. 
Cells were grown over night at 37 °C and, the morning after, were harvested 
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by centrifugation at 10000 rpm for 30 minutes. The pellet was then 
resuspended in 20 ml of lysis buffer (20 mM TRIS pH 7.4, 300 mM NaCl) 
containing a cOmpleteTM Mini Protease Inhibitor Cocktail EDTA-free Tablet 
(Roche). Cells were disrupted by sonication, the insoluble fraction was 
eliminated by centrifugation (10000 rpm, 30 min) while the soluble fraction 
was further purified by heat shock (80 °C, 10 min). The denatured E. coli 
proteins were removed by centrifugation (10000 rpm, 30 min) and the 
remaining solution was purified by ammonium sulphate treatment. PfFt 
ferritin was found as a pure fraction in the 70 % ammonium sulphate 
precipitate and was resuspended in 5-6 ml of buffer (20 mM HEPES pH 7.4, 
50 mM MgCl2) and dialysed against the same buffer. At last, ferritin was 
further purified by gel filtration chromatography (AKTA-Prime system, 
HiLoad 26/600 Superdex 200 pg column, eluent 20 mM HEPES pH 7.4, 50 
mM MgCl2). The highly pure protein was then concentrated by ultrafiltration 
(100 kDa MWCO, Millipore) and the concentration was calculated by 
measuring the UV absorbance at 280 nm using an extinction molar 
coefficient of 31400 M-1cm-1. Protein yield was approximately of 100 mg per 
litre of culture for all ferritin mutants PfFt P77C, PfFt G52C and PfFt 
I124C/K135C.  
  
3.1.2 Archaeoglobus fulgidus ferritin 
 
The gene encoding for the archaea ferritin Archaeoglobus fulgidus (AfFt) 
was already available in our laboratory (PDB 1S3Q). At first the AfFt M54C 
mutant was produced in order to introduce a cysteine residue on the ferritin 
interior cavity surface. The AfFt M54C mutant was subsequently mutated to 
introduce two alanine residues in positions 150 and 151 in order to obtain the 
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AfFt M54C/K150A/R151A mutant, with an octahedral symmetry instead of 
the typical AfFt tetrahedral one90. All the single point mutations were 
introduced one by one in the wild-type gene in the expression vector pET22b 
(Novagen), using a PCR QuickChange Mutagenesis kit (Stratagene) with 
customised primers. The DNAs were transformed into E. coli TOP 10 cells, 
the resulting colonies were screened by DNA sequencing and the plasmid 
bearing the correct mutation was transformed into BL21 (DE3) E. coli cells 
for further protein expression. Each Archaeoglobus fulgidus mutant was 
grown at 37 °C by inoculating a solution of 1 l of LB broth medium and 100 
mg of ampicillin, with 5 ml of an overnight culture grown from one single 
colony. The protein overexpression was then induced with 1 mM IPTG at 
OD600 0.6 and cells were grown over night at 37 °C, to be later harvested by 
centrifugation at 10000 rpm for 30 minutes. The pellet was then resuspended 
in 20 ml of lysis buffer (20 mM TRIS pH 7.4, 300 mM NaCl) containing a 
cOmpleteTM Mini Protease Inhibitor Cocktail EDTA-free Tablet and the 
bacterial cells were disrupted by sonication. After centrifugation, the soluble 
fraction was further purified by heat shock at 80 °C for 10 minutes and the 
denatured E. coli proteins were removed by centrifugation (10000 rpm, 30 
min). The soluble fraction was further purified by ammonium sulphate 
treatment, the precipitated fraction at 70 % ammonium sulphate containing 
the ferritin, was resuspended in 5-6 ml of buffer (20 mM HEPES pH 7.4, 50 
mM MgCl2) and dialysed against the same buffer. Gel filtration 
chromatography onto a HiLoad 26/600 Superdex 200 pg column mounted on 
an AKTA-Prime system (GE Healthcare) finally purified the protein, that 
was obtained in high purity with a yield varying up to 100 mg l-1. The 
concentration was calculated by measuring the UV absorbance at 280 nm 
using an extinction molar coefficient of 33900 M-1cm-1.  
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3.1.3 Humanized Archaeoglobus fulgidus ferritin 
 
The gene encoding for the “Humanized” mutant of Archaeoglobus fulgidus 
(HumAfFt) ferritin was synthesised by GeneArt (ThermoFisher), subcloned 
into a pET22b vector (Novagen) by introduction between the restriction sites 
NdeI and HindIII at the 5’ and 3’ positions respectively, and then 
transformed into BL21(DE3) E. Coli cells for protein expression. The E. coli 
cells were grown in 1 l LB broth medium and ampicillin (100 mg), where 10 
ml of overgrown inoculum were added. The protein overexpression was 
induced at OD600 0.6 by addition of 1 mM IPTG and the cells were grown at 
37 °C over night. The pellet obtained by centrifugation at 10000 rpm for 30 
minutes was resuspended in 20 ml of lysis buffer (20 mM TRIS pH 7.4, 300 
mM NaCl), with a cOmpleteTM Mini Protease Inhibitor Cocktail EDTA-free 
Tablet (Roche). The cells were disrupted by sonication, centrifuged at 10000 
rpm for 30 minutes and the soluble fraction was further purified by heat 
shock at 80 °C for 10 minutes. Denatured E. coli proteins were removed by 
centrifugation (10000 rpm, 30 min) and the soluble fraction was purified by 
ammonium sulphate precipitation. The precipitated fraction at 70 % 
ammonium sulphate containing the ferritin, was resuspended in 5-6 ml of 
buffer (20 mM HEPES pH 7.4, 50 mM MgCl2) and dialysed versus the same 
buffer. A final purification step by gel filtration chromatography (HiLoad 
26/600 Superdex 200 pg column, AKTA-Prime system, eluent 20 mM 
HEPES pH 7.4, 50 mM MgCl2) allowed to obtain a highly pure ferritin with a 
yield ranging between 50-100 mg l-1. The protein concentration was 
calculated by measuring the UV absorbance at 280 nm using an extinction 
molar coefficient of 32400 M-1cm-1.  
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3.1.3.1 Self-assembly assessment 
 
Magnesium-triggered self-assembly in solution was studied by size exclusion 
chromatography (SEC) using a Superdex 200 26/600 GL Column (GE 
Healthcare) mounted on an AKTA-Prime system (GE Healthcare). The size 
of HumAfFt was determined in different conditions (mobile phase: 20 mM 
HEPES pH 7.4 and various MgCl2 concentrations) by comparison with the 
elution volumes of known standard proteins. HumAfFt elution profiles were 
in agreement with the AfFt gel filtration chromatograms in all conditions 
(Figure 6).  
 
 
 
Figure 6: Gel filtration chromatograms on Superdex 200 26/600 GL column. A) HumAfFt 
and C) AfFt in 20 mM HEPES pH 7.4. B) HumAfFt and D) AfFt in 20 mM HEPES pH 7.4 
and 20 mM MgCl2 
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3.1.4 Ellman’s assay 
 
All sulfhydryl moieties introduced in the ferritin mutants listed above were 
tested by Ellman’s assay. Each ferritin was incubated with TCEP (10 eq.) for 
1 hour at room temperature. Excess reducing agent was removed by gel 
filtration chromatography (Desalting column, GE Healthcare) and, 
immediately after, the protein was reacted with the Ellman’s reagent. DTNB 
(stock 100 mM in ethanol, 20 eq.) was added to the protein solution and 
allowed to react at room temperature for 5-15 minutes, until no further 
changes were observed by UV-Vis spectroscopy at 412 nm. The absorbance 
at 280 nm and 412 nm were recorded using as blank a sample containing the 
same amount of Ellman’s reagent in buffer. The protein concentration was 
estimated with the appropriate ferritin extinction coefficient at 280 nm, and 
the TNB concentration was estimated by using a molar extinction coefficient 
at 412 nm of 14150 M-1cm-1. The sulfhydryl per protein ratio (SPR) was 
calculated from the ratio between the Ellman’s reagent concentration and the 
protein concentration. Every experiment was repeated 3 times and the results 
were calculated based on the average of the 3 experiments. All cysteines in 
the numerous mutants were demonstrated to be accessible and reactive 
toward the DTNB reagent. Control reactions were carried out with AfFt and 
PfFt wild type proteins mixed with DTNB reagent in the same conditions 
previously described, to confirm that there is no DTNB reactivity, as both the 
wild type proteins do not contain any cysteine residue within their sequence. 
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3.2 Archaea ferritin permeation study 
 
3.2.1 DTNB-ferritin labelling reaction 
 
The four ferritin mutants PfFt P77C, PfFt G52C, AfFt M54C and AfFt 
M54C/K150A/R151A in buffer 20 mM HEPES pH 7.4 and 20 mM MgCl2 
were all reduced with 3 mM TCEP for 1 h at room temperature. The TCEP 
was removed by gel filtration chromatography on a desalting column (GE 
Healthcare, AKTA Start system) washing with 20 mM HEPES pH 7.4 and 20 
mM MgCl2. The reduced ferritin samples were immediately reacted with a 
40-fold molar excess of DTNB (stock 50 mM in ethanol) for 3 hours at room 
temperature. The UV-Vis absorbance at 412 nm and 280 nm were measured 
to determine the SPR value as previously described, confirming the 
sulfhydryl accessibility of all cysteine residues in every ferritin mutant. The 
unreacted reagent was then removed by ultrafiltration (100 kDa MWCO, 
Millipore) washing with a 20 mM HEPES pH 7.4 and 20 mM MgCl2 buffer. 
The conjugation percentage was determined by mass spectrometry as 
described below.  
 
3.2.2 TNB-labelled ferritin mass spectrometry analysis 
 
All the four ferritin mutants (PfFt P77C, PfFt G52C, AfFt M54C, AfFt 
M54C/K150C/R151C) reacted with DTNB as previously described were 
analysed by LC-MS. Each sample was desalted by extensive dialysis in 
distilled water and in 100 µM EDTA and filtered before analysis. LC-MS 
measurements were performed on a Waters AcquityUPLC connected to 
Waters Acquity Single Quad Detector. A Hypersil Gold C4 column was used 
Chapter 3: Materials and Methods 
 
38 
 
(1.9 μm, 2.1×50 mm). Each sample was eluted with a gradient from 95:5 to 
5:75 water (0.1 % formic acid) : MeCN (0.1 % formic acid) over 6 min, with 
a 0.4 ml min-1 flow rate. The eluted product was observed at 254 nm, in a 
mass range between 250–2000 (ES+) m/z, with a scan time of 0.25 s. Data 
were obtained in continuum mode by setting the electrospray source of the 
MS with a capillary voltage of 3.5 kV and a cone voltage of 50 V. N2 gas was 
used as nebulizer and desolvation gas at a total flow of 300 l h-1. Ion series 
were generated by integration of the UV absorbance at 254 nm 
chromatogram over 1.2–1.8 min range. Mass spectra were subsequently 
reconstructed from the ion series using the MaxEnt 1 algorithm on MassLynx 
software program. 
 
3.2.3 Stopped-flow experiments  
 
Kinetic measurements were carried out on a thermostated Applied 
Photophysic stopped-flow apparatus (Leatherhead, UK). Each protein sample 
was initially incubated with 3 mM TCEP for 1h at room temperature. The 
reducing agent was removed by gel filtration chromatography using a 
Desalting column (GE Healthcare, eluent 20 mM HEPES pH 7.4 and 20 mM 
MgCl2) and the protein was then immediately used for stopped-flow 
measurements. Each ferritin mutant (8-10 µM before mixing (b.m.) in 20 mM 
HEPES pH 7.4 and 20 mM MgCl2) was mixed with DTNB solutions at 
different concentration (from 0.4 to 1.4 mM before mixing (b.m.) in 20 mM 
HEPES pH 7.4 and 20 mM MgCl2). The reaction was monitored by 
observing the UV-Vis absorbance at 430 nm, instead of the classical 
wavelength used for DTNB measurements (412 nm), in order to avoid 
interference of the instrument phototube from the high concentrations of 
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DTNB. While the unreacted DTNB in excess has a significant contribution at 
412 nm, it does not have a high molar extinction coefficient at 430 nm 
(Ɛ430(DTNB)=77.8 M-1cm-1) where the TNB has instead a significant 
absorption. The TNB extinction coefficient at 430 nm was calculated to be 
12205 M-1cm-1, as determined from the 14150 M-1cm-1 extinction coefficient 
at 412 nm117. The collected data were analysed by using a Matlab software 
and the experimental traces were fitted to exponential or bi-exponential 
functions using a Levenberg-Marquardt algorithm. 
 
3.3 Azobenzene-ferritin conjugate for self-assembly photocontrol 
 
3.3.1 4,4’-Dichloracetamido-azobenzene synthesis 
 
A solution of 4,4’-diaminoazobenzene (40 mg, 188 µmol) in dry 
tetrahydrofuran (THF) was placed in an ice bath and trimethylamine (Et3N, 
79 µl, 565 µmol, 3 eq.) was slowly added. After a few minutes, chloroacetyl 
chloride (45 µl, 565 µmol, 3 eq.) was added to the reaction mixture and the 
solution was stirred at 0 °C for 1 hour. An orange precipitate was slowly 
formed and, after 1 hour, the precipitate formation was favoured by cold 
water addition. The precipitate was filtered in vacuo, washed with additional 
cold water, in order to remove any Et3N or chloracetyl chloride excess, and 
with diethyl ether (Et2O) in order to remove any possible 4,4’-
diaminoazobenzene left. The orange precipitate was dried in vacuo and the 
pure product was obtained in 80 % yield (55 mg, 151 µmol). The absence of 
any unreacted 4,4’-diaminoazobenzene was confirmed by ninhydrin staining 
and the purity of the product was checked by NMR spectroscopy and GC-MS 
analysis. Compounds were dissolved in deuterated DMSO (Sigma), poured 
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into small tubes with a 5 mm diameter and NMR spectra were recorded with 
a Bruker Advance 400 operating at 400 MHz and 100 MHz respectively for 
the 1H and 13C nuclei (Figure 7 and 8). The spectra were elaborated with the 
MestReNova program, the chemical shifts were reported in ppm and the 
coupling constants in Hertz.   
 
1H NMR (400 MHz, DMSO) δ: 10.728-10.632 (d, J=38.4, 2H, 
CONH); 8.249-8.226-8.207-8.184 (dd, J1=16.8, J2=9.2, 4H, Ph); 7.826-
7.803-7.774-7.752 (dd, J1=20.4, J2=9.2, 4H, Ph); 4.321-4.304 (d, J=6.8, 
4H, COCH2Cl) 
 
13C NMR (100 MHz, DMSO) δ: 164.984; 142.829; 139.583; 126.465; 
122.946; 43.592 
 
GC-MS(-): m/z = 364 [M-H]-; 168 [M1/2-N]–  
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Figure 7: 1H NMR spectrum in DMSO of 4,4’-dichloracetamido-azobenzene 
Figure 8: 13C NMR spectrum in DMSO of 4,4’-dichloracetamido-azobenzene 
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3.3.2 Azobenzene-labelled ferritin preparation  
 
A solution of PfFt I124C/K135C (4 mg ml-1, in buffer 20 mM HEPES pH 8 
and 150 mM NaCl) was reduced with TCEP (30 eq. per ferritin subunit, 15 
eq. per sulfhydryl moiety, stock 250 mM in buffer) and then incubated at 
room temperature for 1 hour. The reduced ferritin solution was preheated at 
37 °C and 1-butyl-2,3-dimethyl-imidazolium tetrafluoroborate in 20 % v/v 
was added to favour 4,4’-dichloracetamido-azobenzene solubility. The 4,4’-
dichloracetamido-azobenzene (stock 100 mM in DMSO, 5 eq.) was then 
slowly added in 5 additions every 30 minutes (1 eq. per addition). After the 
last addition the reaction was continued for 2 hours at 37 °C under shaking. 
The solution mixture was then centrifuged (14000 rpm, 15 min), the 
precipitate was removed and the supernatant was further purified by gel 
filtration chromatography (G25, eluent 20 mM HEPES pH 8, AKTA Start 
system). The protein was recovered in 82 % yield and the labelling 
percentage was determined by Ellman’s assay to be around 40 %.  
The same reaction condition were used on PfFt wild type and the lack of any 
unspecific 4,4’-dichloracetamido-azobenzene binding was verified by UV-
Vis spectroscopy by the absence of any peak at 370 nm.  
 
3.3.3 Azobenzene-labelled ferritin mass spectrometry analysis  
 
The azobenzene-PfFt sample was analysed by MALDI-TOF mass 
spectrometry by Cogentech s.r.l.. The conjugate sample was desalted on C8 
Empore Disk (3M, Minneapolis, MN) home-made stage tip and resuspended 
in 3 µl formic acid 1 %. 1 µl was spotted on a MALDI sample plate and 
allowed to air dry. Recrystallized sinapinic acid (SA matrix from Thermo 
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Fisher Scientific) was prepared at a concentration of 5 mg ml-1 in 50:50 
acetonitrile/water (0.1 % FA) and spotted directly prior to insertion into the 
mass spectrometer. Matrix-assisted laser desorption ionization (MALDI) 
mass spectra were acquired on 4800 MALDI-TOF/ TOF mass spectrometer 
(Applied Biosystems, Foster City, CA) equipped with a nitrogen laser 
operated at 336 nm laser. Acquisitions were performed in linear mode 
averaging 2500 laser shots in a random, uniform pattern. Ions were 
accelerated with a 20 kV pulse, with a delayed extraction period of 860 ns. 
Spectra were generated by averaging between 500 and 2000 laser pulses in a 
mass range from 4 kDa to 50 kDa. Laser intensity was set to optimize the 
signal-to-noise ratio and the resolution of mass peaks of the analyte. All 
spectra were externally calibrated and processed via Data Explorer (version 
4.7) software118. 
 
3.3.4 Photoinduced isomerization reaction  
 
The azobenzene-labelled PfFt I124C/K135C solution (170 µM, 100 µl in 20 
mM HEPES pH 8) was placed in a quartz cuvette (1 cm path length) and the 
sample was irradiated with a Sutter Lambda XL lamp, with a 300 W Xe light 
source and a 16 nm band pass filter, at 370 nm and 430 nm (Sutter VF5 
tuneable filter wheel). The trans-cis isomerization was accomplished by 
irradiation at 370 nm for 1 hour, until no further changes in the UV-Vis 
spectra were verified. The isomerised sample turned from pale yellow (trans) 
to a strong yellow (cis). The solution was then irradiated at 430 nm for 
different amounts of time up to 24 hours to achieve the cis-trans conversion. 
UV-Vis spectra were recorded either with a UV5600 Spectrophotometer in a 
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0.1 cm path length quartz cuvette or with a NanoDropTM 2000c 
spectrophotometer (ThermoFisher). 
Circular dichroism (CD) spectra were recorded with a Jasco J-810 
spectropolarimeter. Measurements were performed in a thermostated quartz 
cuvette (0.1 cm path length) at 20 °C. The azobenzene-labelled ferritin (25 
µM in 5 mM HEPES pH 8) spectra were acquired as an average of 5 
individual scans and the background recorded with the only buffer was 
subtracted. The wavelength were scanned in continuous mode in the 190-300 
nm range, with a scan speed of 200 nm min-1 and a bandwidth of 2 nm. 
 
3.4 Pyrene-ferritin conjugate for protein oligomerization study and 
imaging in living cells 
 
3.4.1 Pyrene-labelled ferritin preparation  
 
HumAfFt and AfFt M54C (4 mg ml-1, in 20 mM HEPES pH 7.4, 50 mM 
MgCl2) were reduced with TCEP (10 eq.) for 1h at room temperature under 
mild agitation. The conjugation reaction was carried out in 15 % v/v 
acetonitrile to favour N-(1-pyrenyl)maleimide (NPM) solubility. The NPM 
linker (5 eq.) was slowly added to the protein solution and the reaction 
mixture was left under stirring for 4 hours at 37 °C. NPM excess was 
removed by gel filtration chromatography (G25 Desalting, eluent 20 mM 
HEPES pH 7.4, 15 % v/v acetonitrile), cosolvent was removed by dialysis 
against 20 mM HEPES pH 7.4 and, in order to remove excess MgCl2 and 
maintain the protein in its dimeric state 5 mM EDTA was added to the 
dialysis buffer. Extensive dialysis against 20 mM HEPES pH 7.4 was then 
performed to get rid of any trace of MgCl2, EDTA or acetonitrile that could 
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alter the following analysis. Determination of free sulfhydryl was performed 
by Ellman’s assay according to standard procedure as previously described. 
The pyrene-labelled ferritins were obtained in 85 % yield and the labelling 
percentage reached was 75 %, as determined by Ellman’s assay.  
An additional control to assess any possible unspecific interaction of NPM 
with ferritin hydrophobic cavities was carried out. NPM was added to AfFt 
wild type, not bearing any cysteine residue, in the same reaction conditions 
previously described. The unspecific hydrophobic interaction was 
approximately 5 %.  
 
3.4.2 Pyrene-labelled ferritin mass spectrometry analysis 
 
The pyrene-labelled ferritin samples was analysed by MALDI-TOF mass 
spectrometry by Cogentech s.r.l.. Each ferritin sample was desalted on C8 
Empore Disk (3M, Minneapolis, MN) home-made stage tip and resuspended 
in 3 µl formic acid 1 %. 1 µl was spotted on a MALDI sample plate and 
allowed to air dry. Recrystallized sinapinic acid (SA matrix from Thermo 
Fisher Scientific) was prepared at a concentration of 5 mg ml-1 in 50:50 
acetonitrile/water (0.1 % FA) and spotted directly prior to insertion into the 
mass spectrometer. Matrix-assisted laser desorption ionization (MALDI) 
mass spectra were acquired on 4800 MALDI-TOF/TOF mass spectrometer 
(Applied Biosystems, Foster City, CA) equipped with a nitrogen laser 
operated at 336 nm laser. Acquisitions were performed in linear mode 
averaging 2500 laser shots in a random, uniform pattern. Ions were 
accelerated with a 20 kV pulse, with a delayed extraction period of 860 ns. 
Spectra were generated by averaging between 500 and 2000 laser pulses in a 
mass range from 4 kDa to 50 kDa. Laser intensity was set to optimize the 
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signal-to-noise ratio and the resolution of mass peaks of the analyte. All 
spectra were externally calibrated and processed via Data Explorer (version 
4.7) software118. The pyrene-labelled ferritin mass spectra were compared to 
the unlabelled ferritin mass spectra and a high percentage of conjugate was 
found, while only a small amount of unreacted ferritin was detected.  
 
3.4.3 Dynamic light scattering measurements  
 
DLS experiments were carried out with a Zetasizer Nano S (Malvern 
Instruments, Malvern, U.K.) equipped with a 4 mW He-Ne laser (633 nm). 
Measurements were performed at 25 °C, at an angle of 173° with respect to 
the incident beam. All ferritin samples were prepared at 2 mg ml-1 in HEPES 
20 mM pH 7.4 and various MgCl2 concentrations, and were filtered with a 
0.2 µm filter before analysis. Peak intensity analysis was used to determine 
the average hydrodynamic diameters (Z-average diameter) of the scattering 
particles.  
 
3.4.4 Fluorescence spectroscopy measurements  
 
Fluorescence measurements were carried out with a FluoroMax 4 (Horiba) 
spectrofluorimeter with a Haake D8 refrigerated bath at 25 °C and at 
equilibrium. Fluorescence emission spectra of pyrene-labelled samples (30 
µM in 20 mM HEPES pH 7.4) were recorded by 342 nm excitation and 
fluorescence data were collected from 350 to 650 nm. The association 
process dependence on ionic strength was investigated varying 
concentrations of MgCl2 and NaCl, while the dissociation mechanism was 
studied by EDTA treatment. Emission spectra were normalized with respect 
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to the maximum absorption peak of a single pyrene molecule and the 
excimer/monomer ratio (e/m) was used as a relative indicator of the extent of 
excimer formation.  
 
3.4.5 Stopped-flow measurements  
 
Kinetic measurements were carried out on a single mixing stopped-flow 
apparatus (Applied Photophysics, Leatherhead, UK) at 4 °C and 25 °C. 
Samples were excited at 342 nm (6 nm slits) and total emission fluorescence 
was collected with a 360 nm long-pass filter. Association kinetic experiments 
were performed at 5 µM protein b.m. in 20 mM HEPES pH 7.4, increasing 
concentrations of MgCl2 or NaCl, and at constant salt concentration (either 
20 mM MgCl2 or 2 M NaCl b.m.) increasing protein concentrations (5 to 100 
µM ferritin b.m.). Dissociation kinetic experiments were performed at 5 µM 
protein b.m. in 20 mM HEPES pH 7.4 and MgCl2 increasing EDTA/Mg
2+ 
molar ratios or, at a fixed EDTA concentration (20 mM b.m.) increasing 
protein concentrations (5 to 100 µM ferritin in 20 mM MgCl2 b.m.). 
Experimental traces were fitted by using Matlab software, employing a 
double exponential function for magnesium association curves and for EDTA 
dissociation curves. For the NaCl-induced association process, a Gompertz 
function was used to fit the lag phase, while the remaining phases were fitted 
with a quadruple exponential function.  
 
3.4.6 FITC-labelled ferritin preparation 
 
HumAfFt, AfFt and holo-transferrin as controls (2 mg ml-1 in 20 mM HEPES 
pH 7.4 and 50 mM MgCl2) were labelled with fluorescein-isothiocyanate 
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(FITC, 1 mg ml-1 in DMSO, 10 eq.) for 2 hours at room temperature. The 
excess reagent was removed by gel filtration chromatography (Desalting 
column, GE Healthcare, 20 mM HEPES pH 7.4 and 50 mM MgCl2 eluent) 
and the fluorescent dye to protein ratio was determined to be around 60 % by 
UV-Vis spectroscopy using a FITC extinction coefficient of 68000 M-1cm-1 
at 494 nm and a 0.3 correction factor at 280 nm. Labelling percentage was 
confirmed by LC-MS analysis were the Humanized protein was compared to 
the FITC-labelled HumAfFt ferritin. Protein samples were diluted in distilled 
water and 1 mM EDTA, and were loaded on a Waters Acquity UPLC 
connected to Waters Acquity Single Quad Detector. A BEH300 C4 column 
(1.7 μm, 2.1×150 mm) was used. The observation wavelength was set at 
220 nm. The protein was eluted with water (0.1 % TFA) : MeCN (0.1 % 
TFA) gradient from 20 to 65 % over 60 min and a flow rate of 0.25 ml min−1. 
MS mode was set at a scan range of m/z from 200 to 2,000 (ES+), a scan 
time of 0.5 s, electrospray source with a capillary voltage of 3.0 kV and a 
cone voltage of 45 V. N2 gas was used as nebulizer and desolvation gas at a 
total flow of 200 l h-1. Ion series were generated by integration of the UV-
absorbance chromatogram over 2.4–2.8 min range. Mass spectra were 
reconstructed from the ion series by using MassLynx software program. The 
spectra confirmed an approximate 60 % labelling percentage of FITC-
HumAfFt. The FITC-HumAfFt ferritin showed a small amount of unreacted 
protein at 20372 Da (39 %), a first peak corresponding to the mono-labelled 
protein at +389 ± 4 Da (52 %) and a second peak corresponding to the bi-
labelled protein at +778 ± 4 Da (9 %) (Figure 9). 
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3.4.7 FITC-labelled ferritin internalization and visualization into HeLa 
cells  
 
HeLa cells were grown at 37 °C in Eagle’s MEM supplemented with 10 % 
v/v FBS, Glutamax (Invitrogen) and penicillin-streptomycin solution 
(Sigma). The cells were then incubated with FITC-proteins (FITC-HumAfFt, 
FITC-AfFt and FITC-Tf) at the final concentration of 30 µg ml-1 for various 
time (1 h, 3 h, 20 h). 
 
3.4.7.1 Flow cytometry analysis 
 
For flow cytometry analysis HeLa cells were seeded on multiwell plates. 
Cells were incubated with FITC-labelled proteins as described previously, 
washed two times with PBS, detached with trypsin-EDTA (Euroclone), 
washed again with PBS and resuspended in BD-FACS flow buffer. Half of 
each sample was treated with Trypan Blue (TB, Sigma) to quench the FITC 
signal from not internalized membrane-bound nanoparticles. The quenching 
was performed with 0.04 % TB for 10 min on ice. Control cells were treated 
Figure 9: LC-MS spectrum of FITC-labelled Humanized ferritin (green) in comparison with 
Humanized ferritin (blue) spectrum 
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in the same way but without FITC-labelled proteins incubation. 
Internalization before and after TB treatments was measured at the BD 
LSFORTESSA (BD Biosciences, San Jose, CA, USA) equipped with a 488 
nm laser and FACSDiva software (BD Biosciences version 6.1.3). Live cells 
were first gated by forward and side scatter area (FSC-A and SSC-A) plots, 
then detected in the green channel for FITC expression (530/30 nm filter) and 
side scatter parameter. The gate for the final detection was set in the control 
sample. Data were analysed using FlowJo9.3.4 software (Tree Star, Ashland, 
OR, USA).  
 
3.4.7.2 Confocal microscopy measurements 
 
To visualize protein internalization into living cells by confocal microscopy, 
HeLa TagRFP cells were seeded on a μ-slide 8-well ibiTreat (ibidi) and 
induced with 0.2 μg ml-1 of doxycycline. Cells were then incubated with 
FITC-labelled proteins at the final concentration of 30 μg ml-1 for 20 h. 
Before imaging, cells were washed two times with an imaging medium 
(DMEM without phenol red, 10 % FBS, 10 mM HEPES, Glutamax and 
penicillin–streptomycin solution) to eliminate the unbound FITC-
nanoparticles. The confocal laser-scanning microscope used was an Olympus 
FV10i platform equipped with a built-in incubator. Images were acquired 
with a 60×/1.2NA water-immersion objective, LD lasers, 473 nm and 559 
nm, and filter sets for FITC and TRITC. Phase-contrast images were acquired 
simultaneously. 
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3.4.7.3 TfR1 silencing in HeLa cells 
 
Hela cells were transfected with Lipofectamine® RNAiMAX (Life 
Technologies) following standard procedure. The siRNA against TfR1 was 
purchased from Sigma (siRNA ID: SASI_Hs01_00059217). Cells were then 
incubated with 30 µg ml-1 FITC-HumAfFt. After 3 h cells were collected, 
washed and analysed at the cytometer for the FITC fluorescent intensity. The 
FITC intensity was normalized for the FITC intensity of the control (scr) 
samples. 
 
3.4.8 Two-photon fluorescence spectroscopy measurements  
 
Preliminary two-photon fluorescence spectroscopy measurements were 
carried out on pyrene-labelled PfFt P77C, pyrene-labelled HumAfFt and the 
unlabelled proteins as control, at a 416 µM concentration and in 20 mM 
HEPES pH 7.4 and 50 mM MgCl2. Each sample was injected into the 
channels (90.9 µm thick and 90.9 µm wide) of a polymethylsiloxane 
microfluidic device119 and analysed by two-photon fluorescence microscopy. 
 
3.4.8.1 Excitation 
 
Microscope images were acquired through an inverted Olympus IX83 
microscope (Olympus Europe, Hamburg, Germany), equipped with an 
UPLSAPO 10X2 objective (NA 0.4), with a confocal aperture of 80 micron 
for a corresponding theoretical resolution of 680x680 nm (HxV). The 
collinear light beams from a 559 nm laser diode light source and a 690-1040 
nm tuneable Spectra-Physics Mai Tai DeepSee Ti:Sapphire pulsed laser 
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source were injected into the microscope via a FV1200 MPE laser scanning 
confocal device. The samples were illuminated with the tuneable IR light 
from the pulsed source at a constant integrated power of 500 mW over the 
entire range of frequencies. A set of adjusted dichroic mirrors and a 405-540 
nm emission filter (for the non-descanned photon detection) deflected the 
fluorescence emitted radiation into photomultiplier (PMT) detectors for 
integrated light intensity measurements. An optical condenser (0.55 NA) 
collected the transmitted radiation to the bright-field image detector. The 
PMT high-voltages were adjusted such that no pixels were saturated in the 
images. The 1024x1024 pixel fluorescence images (1270.6x1270.6 nm, 10X2 
objective) were collected in line sequential mode. The emitted fluorescence 
from the separated channel device was integrated in the 405-540 nm interval 
and elaborated with Fiji software. Fluorescence emission of pyrene-labelled 
HumAfFt and PfFt P77C were recorded using the unlabelled ferritin signal as 
blank.  
 
3.4.8.2 Emission 
 
The pyrene-labelled ferritin samples were excited at a 755 nm multi-photon 
excitation wavelength with the IR pulsed source at a constant integrated 
power of 500 mW, as previously described. The spectral distribution of the 
fluorescence signal in the UV-Vis range was collected with a PI Acton 
SpectraPro SP-2300 spectrometer equipped with a 150 gr mm-1 horizontal 
diffraction grating and a PI Pixis 256 CCD camera. The emitted radiation 
was collected by a 665 nm cut dichroic mirror placed in a NDD adapter from 
PicoQuant and coupled to the spectrometer by a liquid light guide and 
collection optics. A further short pass filter (Omega Optical 630SP 
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RapidEdge) next to the spectrometer entrance slit reduced the IR excitation 
line by about 7 orders of magnitude. The spectral images onto the CCD 
camera were vertically rebinned and integrated for 100 s. Eventually, the 
background from unlabelled ferritin emission was subtracted to provide the 
two-photon fluorescence emission spectra. 
 
3.4.9 TRITC-labelled pyrene-ferritin preparation 
 
A solution of pyrene-labelled ferritin (4 mg ml-1 in 20 mM HEPES pH 7.4 
and 50 mM MgCl2) was brought to a more basic pH by addition of a 
carbonate solution pH 9 (final concentration 0.1 M). A solution of TRITC 
(tetramethylrhodamine isothiocyanate, Thermofisher, 2.5 mM in DMSO, 1 
eq.) was added to the protein solution and left to react for 4 h at room 
temperature under agitation. The solution was purified by gel filtration 
chromatography (Desalting column, AKTA Start system, GE Healthcare, 
eluent 20 mM HEPES pH 7.4 and 50 mM MgCl2) and a 60 % labelling was 
obtained as determined by UV-Vis spectroscopy, with a protein recovery of 
80 %. 
 
3.4.10 Pyrene-Humanized ferritin internalization and visualization into 
HeLa cells 
 
HeLa cells were grown at 37 °C in DMEM without phenol red and 
supplemented with 10 % (v/v) FBS, Glutamax (Invitrogen) and penicillin-
streptomycin solution (Sigma). Cells were seeded on the 8-well μ-slide 
ibiTreat (ibidi) and after 24 h, TRITC-labelled pyrene ferritins (pyrene-
HumAfFt-TRITC and HumAfFt-TRITC as control) and pyrene-labelled 
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HumAfFt were added at the final concentration of 300 µg ml−1 and incubated 
for 48 h. Just before imaging, cells were washed to eliminate the unbound 
ferritin and then acquired by confocal laser-scanning microscopy. 
Microscope images were acquired through an inverted Olympus IX83 
microscope, equipped a built-in incubator. Images were acquired with an 
UPLSAPO 60X/1.2NA water immersion objective. Confocal aperture was 
120 micron for a corresponding theoretical resolution of 220x220 nm (HxV). 
The images were acquired by both two- or one- photon fluorescence confocal 
microscopy. The collinear light beams from a 559 nm laser diode light source 
and a 690-1040 nm tuneable Spectra-Physics Mai Tai DeepSee Ti:Sapphire 
pulsed laser source were injected into the microscope via a FV1200 MPE 
laser scanning confocal device and used at an excitation wavelength of 755 
nm with a constant integrated power of 500 mW. A set of adjusted dichroic 
mirrors plus a band-pass grating filter (for the TRITC channel) and a 405-540 
nm emission filter (for the non-descanned photon detection) deflected the 
fluorescence emitted radiation into photomultiplier (PMT) detectors for 
integrated light intensity measurements. An optical condenser (0.55 NA) 
collected the transmitted radiation to the bright-field image detector. The 
PMT high-voltages were adjusted such that no pixels were saturated in the 
images. The 1024x1024 pixel fluorescence images (70.7x70.7 nm, 60X 
objective) were collected in line sequential mode. Z-stacks were collected at 
200 nm slice interval, for a total counting time of about 300 s per series. 
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3.5 DNA encapsulation into Humanized ferritin 
 
3.5.1 DNA-labelled Humanized ferritin preparation 
 
A solution of HumAfFt (6 mg ml-1 in buffer 20 mM HEPES pH 7.4 and 50 
mM MgCl2) was incubated with TCEP (10 eq., stock 250 mM in buffer) for 1 
hour at room temperature. The reductive agent was then removed by gel 
filtration chromatography (Desalting column, GE Healthcare). To the 
reduced protein (4 mg ml-1 in buffer 20 mM HEPES pH 7.4 and 50 mM 
MgCl2) a solution of 1,8-bismaleimido-diethyleneglycol (BM(PEG)2) or 
dithiobismaleimidoethane (DTME) or N-(2-aminoethyl)maleimide (NAEM) 
(stock 50 mM in DMSO, 10 eq.) was added and the reaction took place at 
room temperature, under mild agitation for 1 hour. The excess reagent was 
then washed away by gel filtration chromatography (Desalting column, GE 
Healthcare) eluting in HEPES 20 mM pH 7.4. Meanwhile, a solution of Ro-
DNA-SH (1 mM in TRIS 10 mM pH 8, DNA sequence from 5’-3’ 
[ChR6G]GTGTAACACGTCTATACGCCCA[ThiC3], Sigma) was 
incubated with TCEP (10 eq., stock 250 mM) for 1 h at room temperature 
and the excess TCEP was removed with an Oligo Clean & ConcentratorTM 
kit, ZymoResearch. The BM(PEG)2-labelled, the DTME-labelled and the 
NAEM-labelled HumAfFt, all 2 mg ml-1 in buffer 20 mM HEPES pH 7.4, 
were incubated with the previously reduced Ro-DNA-SH (10 eq.) for 1 h at 
room temperature. At the end of the reaction, 50 mM MgCl2 was added to the 
protein solution from a 2 M MgCl2 stock and the mixture was left under 
agitation for additional 30 min. The unreacted Ro-DNA-SH was then 
removed by ultrafiltration (100 kDa MWCO, Millipore) washing with 20 
mM HEPES pH 7.4 and 50 mM MgCl2 until no further Ro-DNA-SH was 
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observed in the flow-through. The conjugated products were then analysed 
by UV-Vis spectroscopy and the labelling percentage was determined by the 
ratio between the Ro-DNA-SH concentration (ɛ530=116000 M-1cm-1) and the 
protein concentration (ɛ280=32400 M-1cm-1). A 160 % labelling per ferritin 
24-mer was found for the Ro-DNA-SH-DTME-HumAfFt conjugate, meaning 
that almost 2 DNA molecules have been successfully encapsulated within the 
ferritin cavity. The Ro-DNA-SH-BM(PEG)2-HumAfFt conjugate showed a 
labelling yield of 22 % per 24-mer and similarly only a 13 % per 24-mer of 
Ro-DNA-SH interacted non-covalently with the interior cavity of NAEM-
HumAfFt conjugate. 
The reaction was performed, in the same conditions previously reported, on 
the HumAfFt where the sulfhydryl reactive moieties were unavailable due to 
a prior reaction with N-methylmaleimide (NMM, 10 eq., 1 h, r.t.) and the 
absence on any unspecifically bound nucleic acid fragment was confirmed.  
 
3.5.2 DNA-labelled Humanized ferritin mass spectrometry analysis 
 
Due to the low percentage of DNA-labelling per monomeric ferritin unit, 
mass spectra of the final conjugates failed to show the peak corresponding to 
the conjugate. However, the linker-HumAfFt conjugate were analysed by 
mass spectrometry analysis to verify the successful first step of the 
conjugation. Samples were analysed by MALDI-TOF mass spectrometry by 
Cogentech s.r.l.. Each ferritin sample was desalted on C8 Empore Disk (3M, 
Minneapolis, MN) home-made stage tip and resuspended in 3 µl formic acid 
1 %. 1 µl was spotted on a MALDI sample plate and allowed to air dry. 
Recrystallized sinapinic acid (SA matrix from Thermo Fisher Scientific) was 
prepared at a concentration of 5 mg ml-1 in 50:50 acetonitrile/water (0.1 % 
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FA) and spotted directly prior to insertion into the mass spectrometer. 
Matrix-assisted laser desorption ionization (MALDI) mass spectra were 
acquired on 4800 MALDI-TOF/TOF mass spectrometer (Applied 
Biosystems, Foster City, CA) equipped with a nitrogen laser operated at 336 
nm laser. Acquisitions were performed in linear mode averaging 2500 laser 
shots in a random, uniform pattern. Ions were accelerated with a 20 kV pulse, 
with a delayed extraction period of 860 ns. Spectra were generated by 
averaging between 500 and 2000 laser pulses in a mass range from 4 kDa to 
50 kDa. Laser intensity was set to optimize the signal-to-noise ratio and the 
resolution of mass peaks of the analyte. All spectra were externally calibrated 
and processed via Data Explorer (version 4.7) software118.  
  
3.5.3 DNA-labelled FITC-Humanized ferritin preparation 
 
The HumAfFt was labelled with FITC as previously described. The DTME 
and BM(PEG)2 linkers were then added to the FITC-HumAfFt and ultimately 
the Ro-DNA-SH were added as described in paragraph 3.5.1. 
 
3.5.4 DNA-labelled FITC-Humanized ferritin cellular uptake 
 
HeLa cells were incubated with Ro-DNA-SH-DTME-HumAfFt-FITC, Ro-
DNA-SH-BM(PEG)2-HumAfFt-FITC at the final concentration of 300 µg ml
-
1. The proteins were then treated and analysed by flow cytometry analysis by 
using the same protocol previously used for HumAfFt-FITC visualization, 
extensively described in paragraph 3.4.7. 
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4. RESULTS AND DISCUSSION 
 
4.1 Archaea ferritin permeation study 
 
In view of the relevance of ferritin as nanocarrier for metals, drugs and 
fluorescent probes, the incorporation of molecules inside the protein cavity is 
an important and challenging step. Commonly employed encapsulation 
techniques exploit the pH-induced cage disassembly to open the ferritin 
cavity and to trap various molecules inside it upon reclosure79. However, as 
previously mentioned, the reassembly is not always complete and hence new 
innovative methods are needed83. In this framework, the recently discovered 
Archaeoglobus fulgidus ferritin has emerged thanks to its unique salt-induced 
assembly properties88. In addition, another archaea ferritin from Pyrococcus 
furiosus has lately emerged as a promising nanodevice98. The success of 
these archaea ferritins is ascribable to their high thermal stability and easiness 
of expression and purification, features that have contributed to their 
increasing use as ferritin versatile scaffolds for various aims120.  
Up to now, several molecules have been encapsulated inside the ferritin 
cavity either by simple diffusion, or by physical entrapment after ferritin 
induced dissociation and reassociation. Simple permeation through the 
ferritin cage would be ideal but, apart from cations encapsulation, only a few 
more reports concerning larger molecules have been described, all regarding 
uniquely mammalian ferritins121. This is due to the restricted channels 
dimensions as even solvated cations (6.5 Å diameter) would need a partial 
dehydration or a ferritin rearrangement in order to penetrate the 3-fold ferritin 
channel (15 Å long and 5-6 Å wide). However, Yang et al. successfully 
reported the charge-selective ferritin uptake of positively charged nitroxide 
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derivatives through the 3-fold channels. The entrance could occur for 
positively charged or polar molecules, while was restricted for negatively 
charged substrates, until anionic residues in the 3-fold channel were replaced 
by histidines (HuHF D131H/E134H) by site-directed mutagenesis122. The 
charge-selective passage could be explained in light of the electrostatic 
potential originated by the positive cluster near the 3-fold entrance and the 
negative amino acid residues along the 3-fold channel that guide the positive 
molecules entrance123. Therefore, while mammalian ferritins have been 
studied and the molecular diffusion inside the cage is known to take place 
through the 3-fold channel and to be restricted to positively charged 
molecules, little is still known about the more recently discovered archaea 
ferritins, in particular concerning the molecular diffusion in and out of the 
protein cavity. A study by Sana et al.88 on the ferroxidase activity of AfFt 
established that the iron cations enter via the same mammalian ferritin 
pathway, the three fold symmetry channels, and not through the peculiar 
Archaeoglobus fulgidus triangular aperture. Indeed, no difference in the iron 
binding and oxidation rates was found comparing AfFt bearing the peculiar 
triangular pores and AfFt K150A/R151A, the “closed” form with the 
classical octahedral symmetry without the 45 Å wide holes. Aside from this 
study on the iron entry, the entrance of larger molecules permeating the 
archaea ferritin cavity has never been investigated and, as Pyrococcus 
furiosus and Archaeoglobus fulgidus ferritins are both emerging as unique 
biological scaffolds, their permeation properties must be explored. Indeed, 
their difference in nature and shape can provide novel possible routes for the 
entry and the encapsulation of molecules, thus expanding the scope of 
possible biotechnological applications.  
 
Chapter 4: Results and Discussion 
60 
 
4.1.1 Archaea ferritin mutants design 
 
To investigate the permeation ability of the newly discovered archaea 
ferritins, a set of four different mutants from AfFt and PfFt, in which cysteine 
residues were placed in topological specific positions, were designed 
expressed and purified124. The set of ferritins included two mutants from 
Pyrococcus furiosus and two mutants from Archaeoglobus fulgidus ferritin. 
The first PfFt mutants, PfFt P77C and PfFt G52C, displayed a reactive 
cysteine residue on the external surface and in the inner cavity respectively, 
while both Archaeoglobus fulgidus mutants, AfFt M54C and AfFt 
M54C/K150A/R151A showed a cysteine facing the inner cavity (Figure 10). 
However, while the AfFt M54C maintained the typical triangular wide pores, 
the AfFt M54C/K150A/R151A mutant displayed the “closed” octahedral 
shape with no pores, common to all ferritins. The internal cysteine 
modification was introduced in a topologically equivalent position inside the 
protein cavity of both PfFt and AfFt.  
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By exploiting the newly introduced sulfhydryl moieties, the ferritin 
permeability was investigated by reaction with a bulky and negatively 
charged molecule such as DTNB (Figure 11) which, with a 5-6 Å diameter 
and a 8-10 Å length, should be incapable of penetrating the ferritin cavity.  
 
 
 
 
 
Figure 10: 3D structures of the ferritin mutants in which one monomer is depicted as green 
ribbon and the cysteine residues are represented in CPK style for clarity. a) PfFt P77C with 
the external cysteine shown as blue spheres, b) PfFt G52C with the internal cysteine 
depicted in red, c) AfFt M54C, with the internal cysteine depicted in purple, d) AfFt 
M54C/K150A/R151A with the internal cysteine in magenta 
 
 
Figure 11: DTNB molecular structure 
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4.1.2 DTNB-ferritin reaction  
 
By analysing the cysteine accessibility and the cage structure of the four 
ferritin mutants, the thiol-disulfide exchange reaction rates between DTNB 
and the cysteine sulfhydryl moieties could be predicted. The solvent exposed 
cysteine on the protein surface of PfFt P77C, would show a complete and fast 
reactivity, while the internal cysteine in AfFt M54C, although accessible 
because of the big triangular pores, would be partially hindered due to its 
internal position. On the contrary, absolutely no reactivity should be observed 
in PfFt G52C and AfFt M54C/K150A/R151A. Surprisingly, however, all 
ferritin mutants were reactive towards DTNB and the cysteine moieties were 
all quantitatively bound as confirmed by UV-Vis spectroscopy by observing 
the TNB absorbance at 412 nm. Sulfhydryl per protein ratios (SPR) found 
were all close to 1, indicating a complete reaction. This evidence was also 
confirmed by LC-MS analysis, where the mass spectra of the four ferritin 
mutants were compared with the ones after DTNB treatment. The mass 
spectra correctly displayed the peak corresponding to the monomeric unit at 
around 20 kDa for the unlabelled protein and a +198±2 Da shifted peak 
corresponding to the TNB molecule for the DTNB reacted ferritins, in 
agreement with the predicted molecular weights (Figure 12). In all samples 
the reaction produced a pure mono-labelled product with the only exception 
of the PfFt G52C mutant, where a 18 % unlabelled protein was found as 
demonstrated by both Ellman’s assay and LC-MS measurements. In 
conclusion, by simple diffusion, a negatively charged and bulky molecule 
such as DTNB was easily uptaken in all archaea ferritin cavities 
demonstrating the more tolerant and permeable nature of the cavity compared 
to the impermeable and selective mammalian ferritin cage.  
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4.1.3 Kinetics of DTNB binding 
 
Kinetics of the thiol-disulfide exchange reaction between the cysteine 
sulfhydryl moiety and the DTNB disulfide were studied by following the 
TNB UV-Vis time-dependent absorbance increase at 430 nm with a stopped-
flow apparatus. The experiments were carried out under pseudo-first order 
conditions, therefore mixing ferritins with different DTNB concentrations in 
large excess and acquiring a complete set of curves for each protein. The 
reactions were followed either to their end or to the instrumental limit of 
1000 s, and the exponential traces were acquired to be further analysed. 
Curiously, while all ferritins were correctly fitted by a mono-exponential 
function, the AfFt M54C traces could be fitted only by a bi-exponential 
function (Figure 13).  
Figure 12: LC–MS spectra of the four ferritin mutants before and after DTNB reaction 
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Figure 13: Kinetic traces of ferritin mutants as a function of DTNB concentrations: A) 
mono-exponential traces of PfFt P77C, B) bi-exponential traces of AfFt M54C, C) mono-
exponential traces of AfFt M54C/K150A/R151A, D) mono-exponential traces of PfFt G52C 
Figure 14: Pseudo-first order plot of the observed rate constants as a function of DTNB 
concentration of PfFt P77C (blue), AfFt M54C (green for the fast phase and red for the slow 
phase), AfFt M54C/K150A/R151A (cyan), PfFt G52C (purple). All reported concentrations 
are after mixing 
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Each set of kinetic traces was fitted and the observed rate constants were 
plotted in a pseudo-first order plot as a function of increasing DTNB 
concentrations (Figure 14).  
A linear dependence of the reaction rates on DTNB concentration was found 
and the apparent second order rate constants for each ferritin were calculated 
from the slopes and are listed in Table 1. 
 
 
 
 
 
The reaction time scale varied considerably among the mutants and, while the 
PfFt P77C reaction was complete within 20 seconds, the PfFt G52C reaction 
was not even complete after 1000 s. As expected, the PfFt P77C mutant with 
the external cysteine displayed the fastest kinetics, almost 200 times faster 
than the PfFt G52C mutant bearing an internal cysteine. The AfFt M54C 
displayed, instead, an intermediate behaviour as, even though the cysteine is 
facing the internal cavity, the DTNB had a facilitated access via the wide 
triangular pores. Curiously, however, this process could only be fitted by a 
bi-exponential function, in which the fastest rate constant was of the same 
order of magnitude determined for PfFt P77C, just 4.5 times lower, and the 
slow rate constant was comparable in magnitude to the rates found for the 
two closed mutants, PfFt G52C and AfFt M54C/K150A/R151A, bearing 
cysteines in the inner cavity. A strong quenching effect on the reaction rates 
Ferritin kOBS (M-1s-1) 
PfFt P77C 908 ± 122 
PfFt G52C 5 ± 1 
AfFt M54C 198 ± 65 (k fast) 
  51 ± 21 (k slow) 
AfFt M54C/K150A/R151A 26 ± 2 
Table 1: Apparent pseudo-first order rate constants for the DTNB-ferritin reactions in the 
various ferritin mutants  
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in the last mutants was then observed, with PfFt G52C as the most 
inaccessible protein barrier with a rate constant five times slower than the 
rate of the closed Archaeoglobus mutant with no pores AfFt 
M54C/K150A/R151A. In addition, from this study, the importance of the 
AfFt M54C triangular pores as a preferential entrance to large negatively 
charged molecules emerged, as the rate constant of the “open” AfFt M54C 
was 8 times higher than the “closed” AfFt M54C/K150A/R151A with no 
pores. The negatively charged molecule entrance could indeed also be 
favoured by the positive clusters at the triangular pore apices. 
Overall these data showed that the diffusion rates of molecules through the 
protein cage barrier could be accurately measured and that the archaea ferritin 
shell was more permeable than the mammalian one, as even bulky negatively 
charged molecules as DTNB could easily pass through it. Interestingly, by 
comparing the uptake of positively charged molecules by mammalian 
ferritins and the permeation of negatively charged molecules in closed 
archaea ferritins, the same time range was observed, suggesting a different 
uptake mechanism or a different packing that alter the cavity permeability. 
The presented evidence sheds light on the archaea ferritin cavity access 
mechanism and will be of relevance for ligand encapsulation and drug 
delivery applications. 
 
4.1.4 DTNB entrance route  
 
Possible entrance routes through the ferritin cage barrier and toward the 
ferritin internal cavity had been examined by structural analysis (PDB: 2JD6 
for PfFt, 1SQ3 and 3KX9 for AfFt with and without triangular pores 
respectively, 2FHA for HuHF). As the 3-fold channels represented the 
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privileged route for iron and molecules entry in both archaea and mammalian 
ferritin a similar route could be proposed for the DTNB entrance. Indeed, 
while the 8 mammalian ferritin 3-fold channels formed by the interaction of 
three adjacent monomers were negatively charged and contained 6 highly 
conserved residues (Asp131 and Glu134 two for each monomer) located at 
the end of the channel (Figure 15C)123, the archaea 3-fold channels presented 
a diminished hydrophilic character. PfFt, similarly to HuHF displayed some 
negative residues on the channel entrance (Asp109, Asp110, Asp111), but 
differed in the hydrophilic character of the central part of the channel, where 
polar and positively charged residue as Tyr114 and Arg117 were found, and 
in the terminal part, where Ala118 and Glu121 were located (Figure 15B)125. 
On the contrary, in the three fold channels of AfFt a mixture of hydrophilic 
and hydrophobic residues along all the channel length was identified. Only 
one negative amino acid was located at the channel entrance (Glu113), while 
the Asp131 and Glu134 in HuHF were replaced by a neutral (Tyr119) and a 
positively charged residue (Asn120) (Figure 15A).  
 
The reduced negative charge in the three fold axes of archaea ferritins might 
explain the facilitated entrance of negatively charged molecules, in 
Figure 15: Profile view of the amino acid lining in the three fold channel in a) AfFt and b) 
PfFt with respect to c) HuHF. The exterior of the shell lies on the left side and the inner 
cavity on the right side of each cartoon as shown schematically. Positive, negative and polar 
residues are depicted as blue, red and green sticks, respectively 
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agreement with the high rate constants reported in the data previously shown. 
In addition, the comparison between AfFt and PfFt 3-fold channels and the 
slightly higher negatively charge of PfFt might also explain the difference 
between the observed rate constants between AfFt M54C/K150A/R151A and 
PfFt G52C, as a 5 times higher rate constant was found in the first protein 
although both ferritins displayed the typical octahedral closed conformation. 
Finally, the 4-fold channel should also be considered as possible route to 
enter the cavity. Indeed, by structural analysis the 4-fold channels of PfFt and 
AfFt M54C/K150A/R151A showed a more polar and hydrophilic character 
than the respective channels in mammalian ferritins. In addition, structural 
evidences identified cations within the 4-fold channels, suggesting a 
hypothetical alternative cation entrance pathway54. Nevertheless, the 
dimensions of the 4-fold channels, being smaller compared to the 3-fold 
channels (4-5 Å vs. 5-6 Å respectively), could not justify the entrance of 
large molecules as they would barely accommodate the entrance of cations. 
Therefore the passage of organic molecules through the 4-fold channels 
would seem even more unlikely than the 3-fold channel hypotesis123.  
Overall, excluding 4-fold channels as possible entrance route due to the 
restricted dimensions and having obtained data in support of the 3-fold 
channel permeation hypothesis, the 3-fold channel pathway was proposed as 
preferred route to encapsulate negatively charged molecules such as DTNB 
within the ferritin cavity. However, as the molecular dimensions of DTNB 
slightly exceeded the 3-fold channel size, rotameric adjustments of relevant 
amino acid side chains must take place during the molecule entrance, thus 
implying a high degree of plasticity of the channel. The flexibility of the 
protein barrier, however, might cause leaking of molecules trapped within the 
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protein cavity and, as the ferritin has shown to be less rigid than predicted by 
the only structural analysis, further investigations will be needed.  
In conclusion, archaea ferritins, with their improved permeability, could be 
employed as new scaffolds for the encapsulation of negative molecules, thus 
widening the potential biotechnological applications of ferritins as 
nanocarriers.  
 
4.2. Azobenzene-ferritin conjugate for self-assembly photocontrol 
 
As the aforementioned encapsulation by permeation, although useful, is 
restricted to molecules with limiting characteristics and the pH-induced 
association/dissociation method is not completely reversible, new methods 
for convenient and reversible encapsulation of any molecule are still needed. 
The last decades have witnessed significant advances in the ability to control, 
manipulate or alter molecular motion of small chemical objects and of 
complex biological molecules. In particular, among various stimuli to 
discipline biological systems, light has been found to be the most appealing 
and outstanding one for numerous reasons. Light can be switched on and off 
quickly, easily and reversibly, and its intensity and wavelength can be simply 
modulated. The light ray can be focused onto a small area and can be 
controlled in remote thus being less invasive. In conclusion, light can offer 
spatially and temporally control over a wide variety of processes126. The most 
remarkable example in nature is the photoreceptive protein rhodopsin which 
can be activated by light-induced isomerization of a covalently attached 
chromophore127. By imitating nature, scientists made an effort to covalently 
link light-responsive molecules to proteins in order to be able to induce 
conformational changes upon photoisomerization of the compounds. Among 
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a variety of molecules, one in particular has emerged for its remarkable 
properties: azobenzene. Azobenzenes are a unique class of chromophores, 
with a peculiarly efficient and clean photochemistry, characterised by two 
aromatic rings linked by a central azo group (N=N) that extend the aromatic 
conjugation. Azobenzenes are ideal molecular switches as they can exist as 
two different isomers, namely the trans (E) isomer and the cis (Z) isomer, 
that are able to photochemically or thermally interconvert rearranging their 
geometry around the azo bond as shown in Scheme 4128.  
 
 
 
 
 
 
 
Usually, the more stable trans isomer is converted by irradiation with a 
wavelength between 320-380 nm into its cis state, which in turn can either 
thermally relax to the more stable trans isomer or be photoisomerized by 
irradiation at 400-450 nm. The photoinduced switch proceeds by absorption 
of a photon that generates an excited state with a decreased energy barrier 
between the two isomeric states and, consequently, the isomers can more 
easily interconvert one into each other. The isomerization yields of the 
process are outstandingly high, thus allowing for the use of low intensity 
lights, and the isomerisation kinetics are remarkably fast, while thermal 
relaxation time is strongly dependent on the specific system126,129,130. All 
Scheme 4: Schematic azobenzene isomerization process 
Chapter 4: Results and Discussion 
71 
 
these excellent features make azobenzenes incredibly photostable and many 
photoswitching cycles can be repeated without any degradation or side effect. 
The only disadvantage is the impossibility to have a full and complete 
conversion from the trans isomer into the cis one, as only a 75 % trans-cis 
conversion is commonly reached while 100 % conversion is always verified 
from cis to trans. From a molecular point a view, the isomerisation leads to a 
strong molecular movement that causes large geometrical and conformational 
changes, reducing the distance between the two carbon atoms in position 4 
and 4’ from 9 Å to 5,5 Å as shown in Scheme 4130. In addition the two 
aromatic rings from a planar geometry in the trans isomer, are brought closer 
together as one of the rings rotates, twisting at an angle of around 90° to 
minimize steric hindrance thus creating a dipole moment that wasn’t present 
before in the symmetrical trans molecule129. These geometrical changes 
strongly affect the UV-Vis absorption of this class of compounds making 
possible to easily study the interconversion reaction by UV-Vis spectroscopy, 
helped also by the high characteristic extinction coefficients of azobenzene 
molecules that are therefore detectable even at low physiologically relevant 
concentrations126.  
Substitution with reactive functional groups is necessary in order to cross-
link the photoswitch to a biological substrate in one or two attachments sites. 
Chemical modification with a mono-functional azobenzene derivative counts 
on its sterical hindrance interference whereas bi-functional azobenzenes are 
usually chemically linked to two strategic positions and can induce strong 
conformational changes. Once again, cysteine is the most exploited amino 
acid for cross-linking as it is easily introduced via site-directed mutagenesis 
in key sites at a precise distance avoiding side reactions with other residues. 
Despite maleimides are the most commonly used cysteine reagents, 
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haloacetamides are often preferred for azobenzene functionalization because 
of the improved stability and robustness of the covalent bond and because of 
the decreased flexibility of the linker. The light-induced isomerization of 
azobenzene molecules covalently attached to biomolecules has been widely 
used in a variety of systems in order to photocontrol peptide structures131–134, 
DNA helicity135, or even protein structures and complex proteic machines 
such as ATP machines136 or protein-folding machines137. Enzymatic activity 
can easily be controlled with azobenzene based light-switches138–140 as well 
as receptors such as glutamate receptors which regulate ion channels, 
therefore offering a tool to control the opening and closure of cellular 
membrane pores141–143. Azobenzenes can also be incorporated into proteins, 
by exploiting E. coli variants expressly designed for this purpose, in the form 
of an unnatural amino acid phenylalanine-azobenzene significantly extending 
the scope of the technique144 or even be useful in gene transcription 
regulation by interfering with the RNA-polymerase145. In addition, the 
stability and efficacy of azobenzenes was also proved in in vivo tests on 
zebrafish where the molecule showed almost comparable photochemistry in 
vivo and in vitro146. In conclusion, any biochemical pathway, no matter how 
much complex, can be potentially controlled by photoregulation just with a 
simple key molecule positioned in the right spot. As several successful 
reports of azobenzene-controlled motion of proteic units have been described, 
the same method could possibly be applied to ferritins in order to 
photocontrol their assembly/disassembly equilibrium. To site-selectively 
introduce an azobenzene molecular switch onto the ferritin surface in a 
topologically selected position, the ferritin and the azobenzene designs must 
be carefully chosen.  
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4.2.1 Ferritin mutant design 
 
The chosen ferritin cage used as a model to test the photoinduced 
disassembly/assembly equilibrium is the Pyrococcus furiosus ferritin. PfFt 
was selected because of its high stability, easiness of production and the 
octahedral symmetry of its cage, similar to the human ferritin packing. 
Indeed PfFt is always assembled as a tetraeicosameric cage and its 
dissociation can only be induced by extreme pH values. In addition, the close 
packing originated from the octahedral symmetry does not allow any large 
molecule to penetrate the cage barrier, as the substance should be small 
enough to be able to cross the 3-fold symmetry channels. Therefore, the only 
chance to encapsulate large or pH-sensitive drugs into such ferritins is by 
means of a controlled and completely reversible dissociation/association 
equilibrium such as the photoisomerization.   
As wild type PfFt did not contain any cysteine residue within its amino acidic 
sequence, two cysteines were introduced by site-directed mutagenesis, 
offering new sites for site-selective conjugation. However, several particular 
conditions were required for an efficient azobenzene cross-linking. Certainly, 
the distance of the side chain sulphur atoms of the engineered cysteines must 
match the end-to-end distance of the azobenzene derivative linker in its trans 
state. Fortunately, the 16 Å length of a trans di-haloacetamide azobenzene 
derivative matched exactly the distance between two parallel amino acids on 
the ith and i+4th helical turns of an α-helical structure. The chosen two amino 
acids on the α-helix must be exposed and accessible to the solvent in order to 
correctly react with the azobenzene derivative in solution. Lastly, the 
azobenzene must be placed in a key spot for the 24-meric assembly involving 
a crucial subunit-subunit interface. By analyzing ferritin crystal structure, 4 
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main interactions were identified as responsible for the cage-like assembly 
(Figure 16): i) the dimer interface at C2 where the A and B helices of one 
monomer interact with the corresponding A’ and B’ helices of a second 
monomer, ii) the three fold channels at C3 where three couples of C and D 
helices form a triangular entrance, iii) the four fold channels at C4 where four 
E helices interact, and iv) the extended area between the three and the four 
fold axes C3-C4 involving several residues of three different monomers. As 
known from several mutagenesis studies, any modification at the C2 interface 
on the A or B helices (respectively in blue and green in Figure 16) would 
only destroy the dimeric building block, while alteration at the C3 and C4 
channels would hardly alter the protein assembly75,78. Even the complete 
rupture of the E helices (red in Figure 16) would probably not be enough to 
destroy the ferritin assembly as several residues had already been removed 
without any consequence for the cage packing76. Therefore, excluding the 
helices A, B and E, the mutations could only be inserted either on the helix C 
or D. The choice fell on the solvent exposed part of the D helix (orange in 
Figure 16) as the C helix (yellow in Figure 16), despite being more 
accessible, established fewer contacts with the interfacing dimers and, due to 
the central position within the monomeric unit, it would hardly drag the hole 
α-helical bundle with it upon azobenzene isomerization. On the contrary, the 
C-terminal part of the D-helix was accessible by the solvent, was involved in 
hydrophobic contacts and hydrogen bonds with the interfacing dimer, and 
was located close to the terminal E-helix. Thus the D helix could more easily 
cause the monomeric unit destabilization by breaking of the 4 terminal 
helical turns.  
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Once identified helix D as the most suited structural motif to introduce the 
two cysteine residues, two amino acids must be carefully chosen for site-
directed mutagenesis. A sequence analysis was carried out to identify the 
conserved key residues among archaea ferritins, as the mutations should not 
be introduced on conserved residues not to alter protein crucial interactions. 
The PfFt D-helix amino acid sequence was compared to the ones from the 
archaea ferritins Thermotoga maritima (TmFt) and Archaeoglobus fulgidus 
(AfFt) (Figure 17). Keeping in mind all the aforementioned criteria three 
possible mutants were explored: i) PfFt K142C/E131C (Figure 18A), ii) PfFt 
I143C/A132C (Figure 18B), iii) PfFt K135C/I124C (Figure 18C). 
Figure 16: PfFt structure with the α-helical units in the monomer highlighted in blue (A), 
green (B), yellow (C), orange (D) and red (E). The monomer main interactions with others 
subunits are highlighted in cyan 
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Among the three possible choices, the first proposal (Glu131/Lys142, Figure 
18, panel A), would mutate the conserved residue Glu131 and would destroy 
a crucial hydrogen bond between Glu131 and Arg64. Two non-conserved 
residues were instead involved in the second option (Ala132/Phe143, Figure 
18, panel B) although both were buried within the dimer interface, thus being 
less exposed to the solvent. The third and last option (I124/K135, Figure 18, 
panel C), would involve residues on the more buried third and seventh helical 
Figure 17: D-helix sequence alignment among PfFt, TmFt, AfFt archaea ferritins. Highly 
conserved residues are highlighted in red squares and the possible 3 set of mutations are 
indicated by colored dots (purple E131/K142, blue A132/F143, red I124/K135) 
Figure 18: Schematic views of the three possible mutations set on the D helix (orange) of 
PfFt. The possible mutated residues are depicted in purple and the interactions between D 
helix residues and the vicinal dimer (cyan) residues are highlighted 
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turns from the C-terminal of the D-helix, instead of the first and fourth helical 
turns of the other proposals, but would not alter any conserved residue. 
Taking into accounts all these considerations, the third mutant was selected 
as first choice, not to alter any conserved residue and preferring solvent 
exposed residues to the hydrophobic buried residues of the second option.  
The chosen mutations were then introduced one by one, by site-directed 
mutagenesis onto the wild type Pyrococcus furiosus ferritin gene. The ferritin 
was overexpressed in E. coli cells and purified in high yields, similarly to the 
wild type ferritin. The accessibility of the newly introduced cysteine residues 
was tested by Ellman’s assay demonstrating a high reactivity.  
 
4.2.2 Azobenzene derivative synthesis 
 
Two cysteine reactive moieties were introduced at the ends of the 4,4’-
diaminoazobenzene molecule, the azobenzene selected as building block. As 
the linkers introduced between the azobenzene molecule and the protein must 
be stable and strong enough to induce the molecular motion, a chloro-
acetamide reactive moiety was preferred to a maleimide group.  
Initially, an acid catalysed synthetic pathway was attempted in which the 
4,4’-diaminoazobenzene was reacted with chloroacetyl chloride and with 
chloroacetic acid as shown in Scheme 5. Unfortunately, the reaction always 
yielded a mixture of multi-functionalised products with 2, 3 or 4 chloracetyl 
moieties, even by varying several reaction conditions such as temperature, 
solvent, molar equivalents of reagent and catalyst.    
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Therefore, the reaction conditions were completely changed and a base-
catalysed reaction was attempted, as shown in Scheme 6. Gladly, the base-
catalysed reaction yielded the desired pure bi-functional product in high yield 
(80 %) as confirmed by NMR analysis.  
 
 
4.2.3 Azobenzene-labelled ferritin preparation 
 
Having obtained both the azobenzene derivative by chemical synthesis and 
the PfFt I124C/K135C ferritin mutant by site-directed mutagenesis, the cross-
linking bioconjugation reaction between the two was attempted. 
Unfortunately, a first issue emerged with the high insolubility of the 4,4’-
dichloroacetamido-azobenzene. The compound was indeed extremely 
insoluble in hydrophilic environments and could only be dissolved in organic 
solvents such as DMSO or DMF. Several reaction attempts at different 
DMSO percentages up to 30 % v/v DMSO were then performed, but the 
Scheme 5: Acid catalyzed synthesis of 4,4’-dichloroacetamido-azobenzene 
Scheme 6: Base catalyzed synthesis of 4,4’-dichloroacetamido-azobenzene 
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immediate precipitate formation could never be avoided, even by slow 
reagent addition or by increasing the temperature to favour the compound 
solubility. In these conditions the cross linking reaction always yielded a very 
poor labelling percentage. The breakthrough came from the employment of 
1-butyl-2,3-dimethyl-imidazolium tetrafluoroborate (Figure 19), a water 
soluble ionic liquid that was able to solubilise the compound in the protein 
hydrophilic environment. Briefly, ionic liquids are salts found in the liquid 
state at room temperature, often made of at least an organic component with 
delocalised charge, which causes poor ion coordination thus preventing the 
formation of a crystal lattice.  
 
 
The ionic liquid was thus employed as cosolvent and its percentage was 
adjusted to find the right balance between protein stability and reagent 
solubility. Finally, by varying reaction conditions such as temperature and 
reagent equivalents and by introducing the reagent slowly over time, the 
crosslinked product was obtained with the best labelling yield achievable (40 
% by Ellman’s assay) and a high protein recovery (82 %). In particular, slow 
reagent addition was crucial in order to give time to the two reactive 
chloracetyl moieties of the azobenzene to react with both cysteine residues. A 
first chloroacetyl moiety will presumably react with the more exposed C135 
and the second reactive moiety will meet by rotation the C124 to only later 
Figure 19: 1-Butyl-2,3-dimethyl-imidazolium tetrafluoroborate 
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react with it. An excessive reagent addition would instead saturate all the 
cysteine residues with one azobenzene molecule for each amino acid yielding 
a 1:1 cysteine/azobenzene ratio, instead of the desired 2:1 ratio with an 
azobenzene molecule bridging two cysteine residues.  
The bioconjugate obtained showed a characteristic pale yellow colour, 
observable by UV-Vis spectroscopy in which a wide band centred at 370 nm, 
typical of azobenzene compounds, was found (Figure 20).  
 
Unfortunately, the labelling percentage (40 % determined by Ellman’s assay) 
was not high enough to observe the azobenzene conjugate by mass 
spectrometry analysis. The MALDI-TOF spectrum obtained showed the main 
unlabelled protein peak with a second broad noisy peak, probably 
corresponding to the azobenzene conjugate, too low to be analysed (Figure 
21). 
Figure 21: Azobenzene-PfFt conjugate MALDI-TOF spectrum 
Figure 20: Azobenzene-PfFt conjugate UV-Vis spectrum 
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The PfFt wild type, without any cysteine residues, was reacted in the same 
conditions of PfFt I124C/K135C as control and, after purification, no trace of 
azobenzene derivative was found confirming the binding of the molecule on 
the cysteine residues and excluding any unspecific hydrophobic interaction.    
 
4.2.4 Photoinduced isomerization 
 
Finally, the photoinduced isomerization reaction was performed on the 
azobenzene-PfFt conjugate in collaboration with the Italian Institute of 
Technology (IIT). The sample was irradiated at 370 nm and UV spectra were 
recorded over time showing a decrease in the 370 nm peak and a smaller red-
shifted peak increase at 430 nm as shown in Figure 22A. The isomerization 
proceeded with a mono-exponential trend (Figure 22B) and was complete in 
60-90 minutes, as verified by the absence of further changes in the UV-Vis 
spectra. The isomerised sample containing the cis azobenzene isomer clearly 
presented a stronger yellow colour as indication of the successful 
isomerization.  
 
Figure 22: Trans-cis isomerization of the azobenzene-PfFt conjugate observed by A) UV-Vis 
spectroscopy and by B) kinetic measurement   
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Isomerization from the cis back to the trans isomer was attempted by 
irradiation at 430 nm, the UV-Vis maximum corresponding to the cis isomer 
identified by subtracting the UV-Vis spectra before and after isomerization. 
Unfortunately, the cis isomer was never able to isomerize back to its trans 
state neither by irradiation at 430 nm or by thermal relaxation, and no 
changes were ever verified by UV-Vis spectroscopy even after over night 
irradiation (Figure 22A, blue spectrum). The lack of success may be due to 
the insufficient power of the 430 nm irradiating lamp. Indeed, a higher 
amount of energy might be needed to bring the unstructured protein segment 
back to its native helical structure. Unfortunately, additional powerful light 
sources available in the laboratory, such as laser sources, did not irradiate at 
the correct 430 nm wavelength required.  
The bioconjugate samples before and after irradiation were analysed by CD 
spectroscopy to observe any appreciable alteration in the α-helical structure. 
However, only tiny alterations were found in the CD profiles of the conjugate 
before irradiation, after 370 nm irradiation and after 430 nm irradiation 
(Figure 23). The low conjugation percentage together with the 
incompleteness of the trans-cis isomerization would probably alter only a 
few helical motifs over 120 α-helices on one single ferritin cage, thus 
resulting in a small alteration not detectable by CD spectroscopy. Therefore, 
only an indirect measure of the azobenzene isomerization state from the UV-
Vis analysis might suggest the success or failure of the isomerization 
reaction, as the protein structural state could not be directly observed by CD 
spectroscopy.  
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4.2.5 Conclusion and future perspectives 
 
Disappointingly, the impossibility to perform the cis-trans isomerization 
prevented the successful conclusion of the ferritin photoinduced assembly-
disassembly in one of the last steps of the project. Hopefully, in the future, a 
stronger 430 nm irradiating source could be capable of inducing the 
azobenzene isomerization thus reversibly closing the ferritin cage. The 
success of this process would open new perspectives for the encapsulation of 
various molecules inside the ferritin cavity and the eventual site-selective 
photo-triggered release in vitro or in vivo.  
 
  
Figure 23: Azobenzene-PfFt conjugate CD spectra before and after irradiation 
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4.3 Pyrene-ferritin conjugate for protein oligomerization study and 
imaging in living cells 
 
Pyrene is a unique fluorescent probe with peculiar spectral features, and its 
N-(1-pyrenyl)maleimide (NPM, Figure 24) derivative has been widely 
employed to label proteins or nucleic acids for various biological 
applications147–154. Any biological scaffold that can populate two distinct 
conformational states can be labelled in key positions with two pyrene 
moieties, in order to study the process involved in the shift between the two 
states by simply observing pyrene spectral changes. With this method it is 
possible to study protein oligomerization, protein folding-misfolding, 
conformational changes147–149, visualization of intracellular RNA150, 
biomolecule signaling151, design of aptamer sensors152,153 and pH sensors in 
cellular organelles154.  
 
 
 
 
 
 
Pyrene versatility is due to a spatially sensitive fluorescence emission that 
displays an ensemble of monomer emission peaks (375-405 nm) and an 
easily distinguishable red shifted broad peak (centred between 440-450 nm) 
corresponding to the excited state dimer called excimer, as shown in Figure 
25155,156.  
Figure 24: N-(1-pyrenyl)maleimide, NPM 
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Excimer formation arises when two pyrene molecules, one in the ground state 
and the other one in the excited state, are located in close proximity (~10-15 
Å) and are involved in a non-covalent π-π stacking interaction147. For an 
efficient excimer formation, the two pyrene molecule must be close and 
parallel-oriented, in a slightly rotated sandwich geometry, at an interplanar 
distance of 3-4 Å155,156. As the two molecules are close but sufficiently 
separated, light can be absorbed by only one of the two moieties, giving two 
pyrene monomers, one in its ground state (M) and one in its excited state 
(M*). The two pyrenes will then interact generating the excited excimer (E*), 
which will then decay, as shown below, giving rise to the peculiar 
fluorescence emission spectra156.  
 
M + M*  M∙M*  E*  M∙M + hν 
  
Excimer formation is facilitated both by the long pyrene excited state lifetime 
(>100 ns) and its energy-accepting properties157. Any change in the 
Figure 25: Pyrene monomer (blue) and excimer (red) fluorescence emission spectra  
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excimer/monomer (e/m) ratio, determined by the fluorescence intensity ratio 
between the excimer band maximum at 445 nm and the monomer peak at 375 
nm, gives informations regarding the distance and the orientation between the 
two pyrene molecules. Therefore, if a protein is labelled with two pyrene 
moieties in two proximal positions in a way that an excimer can be formed, 
any subtle structural change will strongly affect the stacking interactions and 
therefore result in a clear shift in the fluorescence emission147,148,155. The 
correlation between the e/m ratio and the distance of two pyrene molecules in 
a half-helical structure has been studied by Bains et al. and an inverse 
correlation has been found, with an additional contribution from the probe 
mobility and the helix flexibility147.  
Another important information is contained within the pyrene monomer 
emission profile as the so-called “Py value”, given by the intensity ratio 
between the first peak at 375 nm and the third peak at 385 nm, is used as a 
polarity index. The Py value changes with the environment’s polarity and is 
higher in polar solvents where the peak at 375 nm is the predominant one, or 
lower in hydrophobic environments, where the 385 nm peak increases157,158.  
In conclusion, pyrene fluorescence properties are ideal for biological 
investigations as the probe’s high molar extinction coefficient of the probe 
allows studies of proteins in solution at physiologically relevant 
concentrations and its high stability and long fluorescent lifetime give it 
resistance to photodamage and photobleaching159.  
 
  
Chapter 4: Results and Discussion 
87 
 
4.3.1 Humanized archaea ferritin design 
 
Cargo encapsulation within the ferritin cavity is a crucial step that still suffers 
the drawbacks of the most commonly used techniques. Cavity permeation is 
restricted by the molecule charge and dimension, even in the more tolerant 
archaea ferritins, while the pH-triggered encapsulation submits the protein to 
harsh conditions from which the ferritin not always recovers and limits the 
procedure application to pH resistant molecules. Recently, Archaeoglobus 
fulgidus ferritin has emerged as a possible solution to these issues thanks to 
its unique salt-induced self-assembly properties in mild neutral conditions. 
However, archaea ferritin uptake into mammalian cells has never been 
reported up to now, as the only H-homopolymer from human ferritin (HuHF) 
uptake, mediated by the TfR1 receptor, has been described160. Nonetheless, 
the H-homopolymer TfR1 receptor binding site has not been yet identified. 
However, by analysing the three dimensional ferritin structure, with a 
particular regard to the ferritin surface, the most significant accessible areas 
highlighted are the external BC loop with its 19 amino acidic residues and the 
N-terminal segments. The N-terminal and C-terminal fragments are known to 
be not necessary for the TfR1 mediated ferritin uptake, as even by deletion of 
several residues the human ferritin could still be internalised160, suggesting 
that the TfR1 interacts with other ferritin portions to recognize and uptake the 
protein.  
In light of these evidences, to favour the archaea ferritin uptake, an 
engineered archaea ferritin named “Humanized” Archaeoglobus ferritin 
(HumAfFt) was produced, in which the external BC loop was substituted 
with the H-homopolymer human analogue loop. This chimeric protein should 
indeed maintain the salt-induced assembly/disassembly properties typical of 
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Archaeoglobus fulgidus ferritin while being successfully internalised into 
human cells by TfR1 recognition.   
At first, the 3D structure and the amino acid sequence alignment of HuHF 
and AfFt were analysed. From a structural point of view, both human and 
archaea loops were similarly arranged in an antiparallel orientation, while 
from the sequence alignment several differences emerged, as among the 
central portion of the 19 residues loop (from residue 70 to 83, AfFt 
numbering) only 3 residues of the HuHF BC-loop were conserved in the AfFt 
one. Thus, 9 amino acid residues in the centre of the AfFt loop were 
substituted with the residues typical of the human H-homopolymer as shown 
in Figure 26. 
 
 
The chimeric protein was then expressed in E. coli cells. The overexpression 
and the purification protocols were optimised starting from the AfFt 
procedure until the pure protein was obtained with a yield between 50-100 
mg per litre of culture. The protein was then crystallized and its structure, 
determined by X-ray crystallography at a 2.87 Å resolution (PDB 5L69) and 
by cryo-electron microscopy at a 33 Å resolution (Figure 27), confirmed the 
existence of the wide triangular pores and of the correct 24-meric assembly.  
 
Figure 26: Sequence alignment between AfFt, HumAfFt and HuHF. Elements of the 
secondary structure are shown on the top and the conserved residues are highlighted in red 
squares 
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The salt-induced assembly properties of the chimeric ferritin were verified by 
size exclusion chromatography (SEC), confirming identical association 
properties to the native AfFt. The protein was assembled as a dimer at 20 
mM HEPES pH 7.4, while it eluted as a 480 kDa 24-mer at 20 mM HEPES 
pH 7.4 and 20 mM MgCl2 (Figure 6). The mutations on the loop did not 
affect the assembly properties and the chimeric Humanized ferritin was thus 
able to open and reclose by tuning the buffer ionic strength. 
 
4.3.2 Pyrene-ferritin conjugate design  
 
In order to explore and investigate thermodynamically and kinetically the 
HumAfFt assembly/disassembly mechanism from the dimeric to the cage-
like 24-meric state, a conservative mutation M54C was introduced in the 
middle of the B helix and the protein was selectively labelled with N-(1-
pyrenil)maleimide (NPM), a fluorescent pyrene derivative. The NPM 
Figure 27: 3D structure of HumAfFt determined by A) X-ray crystallography with the 
external mutated BC loops in red and B) by cryo-electron microscopy where the HumAfFt 
(orange) is compared with AfFt (cyan) 
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molecule was inserted in a topologically selected position inside the protein 
cavity, at the two-fold axis of the dimer, far from any inter-subunit contacts 
or loop regions in order to avoid any interference with the cage assembly. As 
shown in Figure 28, the distance between two β-carbons of two C54 is 
approximately 14 Å, enough to allow for the excimer formation by π-stacking 
interaction between two pyrene molecules. Any subtle rearrangement or 
structural change in the pyrene-labelled ferritin should affect the reciprocal 
orientation and distance of the two pyrene molecules involved in the excimer, 
thus altering the excimer stacking interaction and therefore resulting in a shift 
in the fluorescence emission. The pyrene fluorescence emission sensitivity 
could thus be used to investigate the assembly/disassembly process.  
 
Figure 28: Ribbon diagram of the antiparallel homodimer structure of HumAfFt (PDB 
5LS9). Two NPM molecules are depicted in magenta sticks bound to C54, establishing a π-π 
stacking interaction, at the dimer interface 
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4.3.3 Pyrene-ferritin conjugate preparation  
 
Optimization of the ferritin-NPM bioconjugation reaction was extensively 
carried out by screening a set of various reaction conditions such as 
temperature, time, reagent equivalents, protein concentration, buffer ionic 
strengths and cosolvent presence. The difficulties met in finding the optimal 
reaction conditions were mainly attributable to the NPM hydrophobic nature. 
Indeed, due to its aromatic pyrene core, NPM was hardly suited for biological 
conjugation in hydrophilic environments. The presence of a cosolvent in the 
reaction mixture was the key ingredient for the success of the reaction, and 
several cosolvents such as DMSO or acetonitrile in different percentages 
were tested. The best results were obtained by employing 15 % v/v 
acetonitrile, the highest amount tolerated by HumAfFt ferritin, and by 
increasing the temperature to 37 °C to favour compound solubilisation. 
Unfortunately, however, even with the cosolvent employment, the NPM 
amount could never be risen above 5 molar equivalents due to precipitate 
formation and consequent protein loss. The labelling yields were then 
improved by longer reaction times and higher protein concentrations. Finally, 
with the best optimised conditions the pyrene-ferritin bioconjugate was 
obtained with a 85 % protein recovery and a 75 % labelling. The labelling 
percentage was determined by Ellman’s assay and MALDI-TOF mass 
spectrometry analysis, since a UV-Vis determination was not reliable due to 
red-shift and hypochromic effect of the pyrene absorption peaks caused by 
micro-environment changes156. As shown in Figure 29A, the mass 
spectrometry spectrum of the conjugate confirmed the presence of two 
species, the unlabelled HumAfFt (observed mass 20248 Da, expected mass 
20243 Da for HumAfFt after the loss of the first methionine residue from its 
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sequence) as the first minor peak and the pyrene-HumAfFt conjugate 
(observed mass 20545 Da, expected mass 20540 Da) with an additional mass 
of 297 Da, proper of the NPM molecule, as the main peak.  
The conjugation reaction was performed in the same conditions on AfFt 
M54C, in order to compare the behaviour of the two proteins in their 
“humanized” and “non-humanized” versions to verify if the 9 mutations 
inserted altered somehow the assembly behaviour. The protein yield and 
labelling percentage were approximately the same as in HumAfFt, as 
confirmed by Ellman’s assay and MALDI-TOF mass spectrometry analysis 
(Figure 29B). Again a first small peak corresponding to the AfFt M54C 
unlabelled protein was found (observed mass 20152 Da, expected mass 
20157 Da for AfFt after the loss of the first methionine residue from its 
sequence) together with the main peak corresponding to the NPM-AfFt 
conjugate (observed mass 20458 Da, expected mass 20454 Da). 
 
Figure 29: MALDI-TOF mass spectra of A) NPM-HumAfFt conjugate and of B) NPM-AfFt 
M54C conjugate 
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In addition, a control to assess the absence of any unspecific interaction with 
ferritin hydrophobic regions was carried out by adding NPM to AfFt wild 
type, with no reactive sulfhydryl moieties, under identical reaction 
conditions. A partial unspecific binding was initially verified and the 
purification conditions were then adjusted to remove any unbound molecule. 
To this end, and once more, the cosolvent turned out to be crucial and by 
optimising the purification protocol the unspecific hydrophobic binding was 
reduced to approximately 5 %. 
 
4.3.4 Ferritin assembly assessment by DLS 
 
In order to verify that the overall oligomerization process had not been 
altered by pyrene-labelling, a DLS study on the ferritin assembly was carried 
out. All ferritins were found to be monodispersed in solution when assembled 
into their 24-meric state, while they were slightly polydispersed when 
dissociated into dimers, an effect probably due to the low signal of the dimer 
(Figure 30).  
Figure 30: DLS intensity by size distribution of A) HumAfFt and of B) AfFt M54C both 
pyrene-labelled (red) and unlabelled (blue) in their dimeric (line) and 24meric association 
state (dotted line) 
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The DLS intensities were reported as a function of the size distribution and 
the average hydrodynamic diameters were extrapolated from the peak 
maxima. The calculated hydrodynamic diameters are listed in detail in Table 
2 and showed an average 5.8 nm diameter for the dissociated state in the 
absence of MgCl2, in agreement with the predicted theoretical value for a 
dimer53, and an approximate 14 nm diameter for the associated state in 20 
mM MgCl2. Both pyrene-labelled HumAfFt and pyrene-labelled AfFt M54C 
ferritins showed similar sizes to the respective unlabelled proteins within the 
error and, in both labelled and unlabelled ferritins, a slightly larger diameter 
was found for HumAfFt compared to AfFt M54C.  
 
  AfFt M54C Pyrene-AfFt M54C HumAfFt Pyrene-HumAfFt 
20 mM HEPES 5,6 Å 5,6 Å 5,9 Å 6,2 Å 
20 mM HEPES, 
20 mM MgCl2 
12,9 Å 14,1 Å 14,8 Å 17 Å 
 
The magnesium dependent DLS titrations confirmed the comparable self-
assembly properties of AfFt and HumAfFt, with and without pyrene, and 
showed a complete transition within 5 mM MgCl2 (Figure 31).  
 
 
 
 
Table 2: Calculated hydrodynamic diameters of both pyrene labelled and unlabelled 
ferritins in absence or presence of magnesium cations 
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4.3.5 Ferritin assembly/disassembly assessment by fluorescence 
spectroscopy 
The HumAfFt salt-induced self-assembly process was extensively studied in 
comparison with the AfFt M54C oligomerization process, by exploiting the 
pyrene sensitive fluorescence emission and by employing PfFt P77C as 
standard. Pyrococcus fulgidus ferritin was chosen as standard as it is uniquely 
found as 24-meric assembled cage in solution, thus being an ideal assembled 
cage standard independent of salt concentrations. In addition, the pyrene 
molecules linked to the PfFt P77C external cysteines were placed at a 24 Å 
distance, too far from each other to form an excimer by stacking interaction, 
but ideal to represent a pyrene monomer standard.   
The set of three pyrene-labelled ferritins (pyrene-HumAfFt, pyrene-AfFt 
M54C, pyrene-PfFt P77C) were analysed by fluorescence spectroscopy at 25 
°C (excitation at 342 nm). As reported in Figure 32, only the pyrene 
monomer fluorescence emission was present in PfFt P77C, while in AfFt 
Figure 31: DLS scattered light intensity as a function of MgCl2 concentration of HumAfFt 
and AfFt M54C both pyrene-labelled and unlabelled 
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M54C and HumAfFt an additional broad band centred at 445 nm appeared, 
thus confirming the predicted excimer formation. 
 
Surprisingly a higher amount of excimer was found in HumAfFt although the 
protein differed from AfFt M54C by only 9 residues on the loop between 
helices B and C and the superposition of the two structures did not highlight 
any significant repositioning in the residue 54. For an efficient excimer 
formation, two pyrene molecules must be stacked in a parallel orientation 
allowing for a π-π interaction to take place, and these mutations on the loop 
could possibly slightly affect the relative orientation and distance between the 
two pyrene moieties147. 
The AfFt wild type, bearing no cysteines, was also analysed by fluorescence 
spectroscopy to investigate the possible contribution of the 5 % unspecific 
hydrophobic labelling. As NPM alone is fluorescent only when reacted with a 
sulfhydryl moiety, due to a quenching effect of the maleimide double bond, 
no pyrene fluorescence spectra was observed, confirming the absence of any 
contribution to the conjugate fluorescence spectra from the unspecifically 
bound molecules. The unlabelled protein contribution to the fluorescence 
spectra was also analysed and found to be inexistent as expected.  
Figure 32: Fluorescence emission spectra of the pyrene-labelled ferritins obtained by 
excitation at 342 nm 
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An additional control to verify that the excimer arose from the inter-
molecular interaction of two close pyrene molecules and not from intra-
molecular interactions of pyrene aggregates from different cages was carried 
out and the fluorescence spectra were recorded at different dilutions both 
with and without magnesium cations. While the total fluorescence decreased 
the excimer/monomer ratio, an index of the total excimer amount, remained 
constant demonstrating that the excimers were formed by intermolecular 
pyrene stacking (data not shown).  
Remarkably, in the tetraeicosameric state, upon cation-triggered 
oligomerization, the overall amount of excimer decreased in both pyrene-
HumAfFt and pyrene-AfFt M54C, as shown in Figure 33, probably due to 
movements at the dimer interface that caused a destabilization of π-π stacking 
interactions between the two pyrene moieties.  
 
Moreover, the excimer amount was successfully restored after EDTA 
addition (equimolar to the MgCl2 in solution), suggesting that the chelating 
agent ability could promote protein disassembly by removal of magnesium 
Figure 33: Reversibility assessment of the assembly-disassembly mechanism. Fluorescence 
spectra of A) pyrene-HumAfFt and B) pyrene-AfFt M54C in the absence of salts (red), in 
the presence of 50 mM MgCl2 (green) and after 50 mM EDTA addition (blue) 
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cations and that the excimer content could be related to the association state 
of ferritin (Figure 33).  
To corroborate that the fluorescence excimer band variation was related to 
the oligomerization process and was independent of the ionic strength, the 
fluorescence emission was measured at fixed ionic strength using different 
amounts of either MgCl2 or NaCl. According to the Debye–Hückel model, 
the experiment was carried out at two different ionic strength conditions: at 
low salt concentrations (i.e. 150 mM NaCl or 50 mM MgCl2), where the 
protein was associated in the 24-meric state only in MgCl2, and at high salt 
concentrations (i.e. 600 mM NaCl or 200 mM MgCl2), where the protein was 
associated in both salts. As shown in Figure 34, the excimer content without 
salt and in the first condition at 150 mM NaCl were similar, in agreement 
with a dissociated state. In contrast, at 50 mM MgCl2, therefore at an equal 
ionic strength as above, the excimer content revealed the presence of an 
associated state for both proteins (Figure 34). Moreover, the pyrene monomer 
emission profile of PfFt P77C did not change at various salt concentrations, 
excluding any ionic strength influence on the pyrene fluorescence emission 
(data not shown). 
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The fluorescence emission dependence on the protein oligomerization state 
was thus investigated by monitoring magnesium-induced association at 
equilibrium. By exploiting the excimer/monomer ratio (e/m) as an index of 
the extent of excimer formation, the association process was investigated as a 
function of MgCl2 concentration. A sigmoidal curve was found, suggesting a 
high cooperativity within the oligomerization process, with a transition 
between 0.5 and 2 mM MgCl2 and a complete assembly at about 5 mM 
MgCl2 in both ferritins (Figure 35). Apart from small differences between 
AfFt M54C and HumAfFt profiles, the overall assembly process was not 
drastically altered by mutation of the 9 residues on the BC loop in HumAfFt.  
 
 
 
Figure 34: Assessment of the correlation between oligomerization state and excimer 
fluorescence. Fluorescence emission spectra of A) HumAfFt and B) AfFt, without any salt 
and at two different fixed ionic strengths for either MgCl2 or NaCl. Spectra in the absence of 
any salt (red) and 150mM NaCl (blue) correspond to a dimeric state, while the profiles at 
600 mM NaCl (cyan), 50 mM (green) and 200 mM (black) MgCl2, correspond to the 
associated state 
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By comparing the sigmoidal curves obtained by fluorescence measurements 
and dynamic light scattering analysis, the overall shapes of the curves 
perfectly matched (Figure 36), confirming that the indirect pyrene 
fluorescence changes observed were actually representative of the protein 
assembly state, thus validating the fluorescence method employed.  
Figure 35: Thermodynamic study of Mg2+-triggered oligomerization process. Fluorescence 
e/m ratio is shown as a function of magnesium concentration. The curves were obtained at 
equilibrium at 25 °C for both pyrene-labeled HumAfFt (red) and AfFtM54C (green) and 
show a highly cooperative transition 
 
. 
 
Figure 36: DLS titration compared with fluorescence titration as a function of MgCl2 
concentration. DLS measurements for (A) AfFtM54C and (B) HumAfFt, native (blue) and 
pyrene-labeled (red), are compared with fluorescence measurements on pyrene-labeled 
ferritins (black). All the measurements show a cooperative association not altered by pyrene 
labelling 
 
. 
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Despite being an indirect method, the fluorescence investigation has the 
advantage to be faster and to require smaller amounts of sample than DLS. In 
addition, by observing the fluorescence signal, fast kinetics could be 
observed that were otherwise not detectable by DLS analysis.  
In light of the surprisingly strong effect observed by employing Mg2+ cations, 
the subunits assembly was analysed in terms of possible contributions to 
specific binding within the three-dimensional crystallographic structure (PDB 
5LS9) by using PISA software (CCP4 suite). No significant evidence of Mg2+ 
presence at the interface between dimers was observed. In fact, as it was 
previously reported by Sana et al.88,90, it was evident that the hydrophobic 
network connecting the dimer interface played a key role in stabilizing the 
cage structure in high ionic strength buffers. In turn, divalent cations were 
found to occupy the AfFt ferroxidase centre under conditions of iron 
deficiency, through explicit coordination provided by Asp52, Glu19 and 
His55, according to AfFt numbering87, and several metal cations as Mg(II), 
Mn(II), Cd(II), Zn(II), Tb(III) were also observed in the three sites of the 
ferroxidase centre of several other proteins54,60,161,162. In the light of these 
observations, it might be hypothesized that coordination of Mg2+ in the 
ferroxidase centre can assist the assembly process by exerting some subtle 
conformational rearrangement within the dimeric species, thus explaining the 
different behaviour respect to a monovalent cation. 
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4.3.6 Ferritin assembly/disassembly kinetics  
 
By monitoring the pyrene fluorescence changes over time with a stopped-
flow apparatus, the kinetics of the salt-induced oligomerization process were 
studied. The fluorescence emission was observed as total fluorescence with a 
360 nm cut-off. The areas under the curve (AUC) were thus calculated for the 
fluorescence profiles of the dimeric and 24-meric ferritin states at equilibrium 
and the highest AUC was found in the protein with a higher excimer content, 
the ferritin dimer (Figure 33). Therefore, a fluorescence decrease over time 
was expected upon protein oligomerization. Initial measurements revealed a 
surprisingly fast time course with a magnesium-triggered assembly complete 
within 10 ms, which is quite close to the dead-time of the stopped-flow 
apparatus (1-2 ms) and therefore impossible to follow by stopped-flow 
measurements at 25 °C. However, by lowering the temperature to 4 °C a 
clear decaying exponential curve was recorded. Despite being always close to 
the instrumental time limit and despite the loss of the initial data due to the 
impossibility to observe the processes under 10 ms, some semi-quantitative 
estimates on Mg2+-induced association could still be obtained.  
Fluorescence emission decreased upon Mg2+ addition with a double 
exponential trend and the reaction was complete within 25 ms, as shown in 
Figure 37. Reaction rates increased proportionally with both Mg2+ and 
protein concentration with a major contribution from the protein 
concentration (Figure 37B). The pyrene-HumAfFt and pyrene-AfFt kinetics 
were comparable, and as an example the only pyrene-HumAfFt kinetic traces 
were reported in Figure 37. Control experiments in which the protein 
dissolved at very low ionic strength (i.e. buffer alone, 20 mM HEPES pH 
7.4) was injected against an identical sample or against the only buffer 
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confirmed the absence of any time-dependent changes in the fluorescence 
signal (data not shown). 
 
The EDTA-triggered dissociation process was slower than the assembly and 
was measured both at 25 and 4 °C. Faster dissociation rates were observed at 
higher temperatures, with completeness reached in 0.1 s at 25 °C and in 0.25 
s at 4 °C. The dissociation kinetics showed a biphasic time profile, dependent 
on EDTA concentration but independent of protein concentration (Figure 38), 
as expected. Once more there were no appreciable differences between the 
pyrene-HumAfFt and the pyrene-AfFt M54C profiles.  
 
 
 
 
Figure 37: Association kinetics as a function of (A) MgCl2 concentration and (B) ferritin 
concentration recorded at 4 °C showing a fast bi-exponential behavior complete in 25 ms 
 
. 
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Since the kinetic reaction in the presence of magnesium cations appeared to 
be too fast to be properly studied, the slower Na+-induced association process 
was also investigated. In comparison with magnesium, higher salt 
concentrations were required to monitor Na+-triggered association as the 
oligomerization was complete only at 500 mM NaCl89. The assembly showed 
much slower rates and a multiphasic kinetic profile (Figure 39) with an initial 
lag phase (Figure 39A’ and 39B’), typical of a nucleation process commonly 
found in protein oligomerization163,164, that evolved in four exponential 
phases towards the end of the reaction, which was reached only after 20-30 
minutes at 25 °C. These changes in the total fluorescence emission over time, 
could be due to multiple pyrene rearrangements during the assembly. 
Additionally, while the association rates were proportionally increasing with 
NaCl concentration, at fixed NaCl concentration and varying protein 
concentration the reaction rates were approximately constant.  
Figure 38: Dissociation kinetics as a function of (A) ferritin concentration (B) EDTA/Mg2+ 
molar ratio, recorded at 4 °C showing a fast bi-exponential behavior complete in 250 ms 
 
. 
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Sodium-triggered association showed a markedly different behaviour with 
respect to the magnesium-induced process, not only because of the higher 
amount of salt required but also because of the longer times and the different 
influence of protein or salt concentration on the reaction rates. This evidence, 
although difficult to interpret and analyse due to the complexity of the 
aggregation mechanism, seem to suggest that a different mechanism might be 
involved in the magnesium-triggered association compared to the sodium-
triggered one. Unfortunately, even though the curves had been 
mathematically fitted by multi-exponential functions, due to the complexity 
of the mathematically analysis and the intrinsic difficulty in extracting a 
mechanicistic meaning from the data without a supporting kinetic model165, it 
was impossible to deeply understand the meaning of these findings. 
However, the data reported in this thesis are a first step in unravelling the 
Figure 39: Association kinetics as a function of (A) NaCl concentration (B) ferritin 
concentration, recorded at 25 °C showing a multi-exponential behavior not complete in 
1000 s. In the close up views A’ and B’ the initial lag phases respectively as a function of 
NaCl and ferritin concentration were shown  
 
. 
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details of the aggregation process of ferritins, by using a simple spectroscopic 
technique such as fluorescence spectroscopy (as opposed to more 
sophisticated methodologies, i.e. DLS and small-angle X-ray scattering) that 
hopefully, in the future, will be of help in disclosing the single steps of the 
process. In addition, these evidences will offer new insights for the controlled 
assembly/disassembly crucial for cargo encapsulation in mild physiological 
conditions of both AfFt and HumAfFt. Indeed magnesium-triggered 
assembly represents a convenient alternative to the NaCl-induced process as 
Mg2+ can induce a faster cage closure with lower salts amounts, thus 
potentially representing a marked improvement for the synthesis of drug 
delivery nanodevices. 
 
4.3.7 Humanized ferritin cellular uptake 
 
HumAfFt was expressly designed with the aim of creating a protein cage 
with the peculiar characteristics of AfFt ferritin, which were assessed as 
previously described, and with the TfR1-recognition motive typical of the 
human ferritin H-homopolymer. Indeed, as TfR1 is overexpressed in several 
tumour cell lines, the successful recognition of HumAfFt would open new 
possibilities in exploiting the ferritin nanocages for cell-targeted delivery of 
probes for diagnostic or therapeutic purposes. Thus the humanized ferritin 
HumAfFt cellular uptake was studied both by flow cytometry analysis and by 
confocal microscopy in collaboration with the Italian Institute of Technology 
(IIT).   
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4.3.7.1 Flow cytometry analysis 
 
HeLa cells, with their high level of TfR1 expression, were chosen as tumour 
cell line testers for the HumAfFt uptake receptor. A set of three different 
proteins, AfFt, HumAfFt, and transferrin (Tf, as control for TfR1 uptake), 
were labelled with a FITC fluorophore. The proteins were incubated with 
HeLa cells for different amounts of time (1, 3, 20 h) and were then analysed 
by flow cytometry (Figure 40A). As expected, transferrin was highly 
internalised in all cells, while AfFt ferritin was excluded (5 % uptake at 1 h, 
less than 20 % at 20 h). However, the engineered chimeric ferritin HumAfFt 
was actively uptaken already after 1h of incubation at a much higher 
percentage (81 % at 1 h and 90 % at 20 h) than the native AfFt. The increased 
uptake after 20 h, as it involved both AfFt and HumAfFt, might be due to an 
unspecific uptake by pinocytosis, while the initial uptake would probably 
involve a specific receptor-mediated internalization.  
In addition, to confirm that the internalization was actively mediated by 
TfR1, the cellular uptake was analysed by FACS after blocking the receptor 
expression by siRNA transfection. Cells were transfected with a scrambled 
RNA sequence (scr) as control and with a specific anti-TfR1 siRNA for 24 or 
48 h, and the HumAfFt internalization percentage was analysed by FACS, 
confirming the involvement of TfR1 in HumAfFt uptake, as a 50 % decrease 
was recorded after anti-TfR1 siRNA transfection for 48 hours (Figure 40B).  
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4.3.7.2 Confocal microscopy measurements 
 
FITC-HumAfFt internalization by HeLa cells was also studied by confocal 
microscopy, where the HeLa cell line used was the TagRFP Hela, HeLa cells 
with a red labelled nucleus. Both FITC-HumAfFt and control FITC-Tf as 
control were incubated for 20 h with the HeLa cells and the non internalised 
proteins were washed away just before imaging. The confocal images 
confirmed a high internalization of HumAfFt and highlighted a cellular 
distribution both in the cytoplasm and in the perinuclear space with a 
spherical pattern that might suggest a clathrin-coated endocytosis pathway, 
typical of TfR1 uptake (Figure 41). 
 
  
Figure 40: A) FITC labelled-proteins uptake by HeLa cells measured by flow cytometry 
analysis and reported as percentage of cells internalizing the nanoparticle, B) HumAfFt 
uptake decrease in HeLa cells by TfR1 silencing measured by flow cytometry 
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4.3.8 Two-photon absorption and emission spectroscopy measurements on 
pyrene-HumAfFt 
 
HumAfFt TfR1-mediated uptake into mammalian cells might facilitate the 
site-selective delivery of selected cargos within tumour cells such as HeLa 
cells. The already available pyrene-HumAfFt ferritin was thus employed for 
ferritin visualization into HeLa cells, in order to test this new nanoscaffold as 
potential bioimaging diagnostic tool for two-photon fluorescence microscopy 
(TPFM). Two-photon excitation is a fluorescence technique involving the 
excitation of a fluorophore by the simultaneous absorption of two low energy 
Figure 41: Protein internalization into living HeLa cells observed by confocal microscopy. 
A) FITC-protein internalized in HeLa TagRFP cells were shown as single, merged channels 
and overlay images (scale bar 40 µm). B) Magnified views of the white squares highlighted 
regions in panel A showing the merged channels and the overlay for transferrin and 
HumAfFt (scale bar 10 µm) 
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photons, commonly infrared (IR) photons. TPFM has several advantages 
over the canonical one-photon fluorescence confocal microscopy among 
which are: i) the IR light with a longer penetration depth due to the decreased 
absorption by biological samples and ii) the minimized photobleaching and 
photodamage, useful for non invasive biological studies.166 In this 
framework, molecules with extensive π-conjugation such as pyrene, have 
emerged as ideal systems for two-photon fluorescence microscopy, thanks to 
their long fluorescence lifetime and electronic stability providing more 
sensitive microscopic images than currently used dyes166,167.  
Preliminary two-photon measurements were then carried out, in collaboration 
with the Italian Institute of Technology, on pyrene-labelled HumAfFt and 
pyrene-labelled PfFt P77C in order to study the behaviour of the pyrene 
fluorophore in its excimeric and monomeric states respectively by two-
photon fluorescence microscopy. All measurements were performed by 
employing the corresponding unlabelled ferritins as blanks. The conventional 
single photon absorption spectra (Figure 42A) were then compared with the 
spectra acquired by measuring the total fluorescence emission as a function 
of the excitation wavelength (Figure 42B). As expected, the overall shape of 
the two- and one- photon spectra were in good agreement except for small 
differences due to the diverse absorption/emission cross sections of the 
electronic processes involved, a common feature observed in numerous 
experimental studies168,169. The frequency shift occurring between the half of 
the two-photon and the one-photon excitation wavelengths could also be 
ascribed to the different excitation cross-sections.  
The two-photon total fluorescence spectra reported in Figure 42D were then 
acquired by excitation at a 755 nm wavelength, the maximum in both pyrene 
monomer and excimer excitation spectra. The comparison between the two-
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photon fluorescence spectrum at 755 nm (Figure 42D) and the one-photon 
fluorescence spectrum at 342 nm (Figure 42C) showed similar excimer 
profile shapes and a slightly different shape for the monomer profile.  
 
 
 
 
 
 
 
 
 
 
In addition, both two-photon fluorescence spectra presented a red shifted 
signal possibly due to non-radiative decays.  
The overall spectral behaviour of pyrene monomer and excimer was mostly 
preserved in the single and two-photon approach, with a maintained 
remarkable difference between the pyrene monomeric profiles and the pyrene 
excimer profiles typical of the pyrene-labelled HumAfFt.   
 
  
Figure 42: Pyrene excimer and monomer absorption and emission curves. In all panels, 
pyrene-labeled PyFtP77C and pyrene-labeled HumAfFt corresponding to monomer and 
excimer pyrene are shown in blue and red respectively: A) UV-Vis absorption spectra, B) 
Spectral integrated fluorescence as a function of the two-photon exciting wavelength, C) 
Fluorescence emission spectra recorded exciting at 342 nm, D) Two-photon fluorescence 
emission spectra recorded exciting at 755 nm 
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4.3.9 Pyrene-HumAfFt cellular uptake and visualization by two-photon 
fluorescence microscopy 
 
Finally, to evaluate the performance of this novel nanodevice as active 
fluorescent probe for two-photon confocal microscopy, live HeLa cells 
expressing high levels of TfR1 receptor and capable of HumAfFt ferritin 
uptake were incubated with pyrene-labelled HumAfFt-TRITC and imaging 
studies were carried out by TPFM. HumAfFt internalization process was not 
altered by pyrene-labelling as confirmed by TRITC signal, detected with one- 
photon excitation (Figure 43A, A’). Once more the ferritin was found 
localised within the cytoplasm and the perinuclear space.170 By observing the 
same cells, but switching to TPFM imaging, the pyrene excimer emission 
was detected in the same locations where the TRITC signal was recorded 
(Figure 43B, B’) and a partial co-localization was highlighted (Figure 43C, 
C’ and 43D, D’). Unfortunately, only a partial overlap between pyrene and 
TRITC signals was found due to differences attributable to the diverse 
techniques employed. Indeed the two imaging acquisitions had intrinsic 
different integrated z-section, smaller in the TPFM compared to confocal 
imaging with a minor total number of visible particles in a single plane. In 
addition, as to switch from the one-photon to the two-photon mode there was 
an intrinsic delay time and as the HeLa cells observed were alive and not 
fixed, intracellular compartments moved and rearranged. However from the 
same spherical pattern of both pyrene and TRITC emission and from the 
vicinal localization it could be confirmed that the emission corresponded to 
the ferritin fluorophore thus successfully reporting the employment of the 
excimer-based pyrene functionalised nanoparticle for TPFM imaging. In the 
future these findings could enable the creation of a novel and versatile set of 
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pyrene-excimer based ferritin probes for diagnostic and biomedical 
application based on the high intensity excimer fluorescence and on the 
ability of HumAfFt to target the overexpressed TfR1 receptor in human 
cancer cells. 
 
  
  
Figure 43: Confocal imaging of live HeLa cells incubated with pyrene-HumAfFt-TRITC. 
Images were acquired at one and two-photon excitations to detect respectively the TRITC 
(A) and the pyrene excimer emission (B). Merged signals and the overlay with the DIC 
image are shown in C and D, respectively (scale bar is 10μm). Magnified images of the 
highlighted regions are showed in corresponding panels A’, B’, C’ and D’(scale bar is 5μm) 
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4.4 DNA encapsulation into Humanized ferritin 
 
The remarkable structure together with the peculiar assembly properties of 
the chimeric Humanized ferritin nanocage and the successful recognition by 
the TfR1 receptor make HumAfFt an appealing and ideal nanoscaffold for 
incorporation, site-selective delivery and release of any payload in the 
cytoplasm of cancerous cells overexpressing TfR1. With its 8 nm cavity, 
ferritin can host both small and large cargos, shielding them from degradation 
and rapid clearance until the target is reached. Nucleic acid sequences, for 
instance, often need a delivery vehicle to be transported through the blood 
stream and to be delivered site-selectively into the cell, as they are easily 
subjected to enzymatic degradation and are too negatively charged to cross 
the cellular membrane171. Despite these issues, drugs based on the use of 
DNA or RNA sequences are emerging for their remarkable efficacy in the 
treatment of several diseases172 as they are selective and versatile drugs 
which could potentially target any gene with high specificity. Therefore, the 
future success of nucleic acid based therapies lies in the research for well 
suited delivery vehicles, capable of protecting the short sequences from 
degradation both in vitro and in vivo until the target is specifically reached. 
Commonly employed vehicles are the viral or non-viral systems173,174 but, 
despite the high transfection efficiency of viral vectors, non-viral vectors are 
often preferred due to immunological issues175. In this framework Li et al. 
successfully described the encapsulation of a small interfering RNA (siRNA) 
into a non-viral vector like the human ferritin cage171. However, the 
encapsulation procedure employed is not ideal as the molecules are entrapped 
by pH-induced dissociation and reassociation of the ferritin cavity, thus 
possibly damaging both the protein and a sensitive molecule such as a nucleic 
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acid sequence by lowering the pH down to 2. On the contrary, Humanized 
archaea ferritin with its unique triangular pores might facilitate the nucleic 
acid entrance by electrostatic attraction of the positive clusters on the 
triangular pore apices or, otherwise, it could trap the molecule inside the 
cavity by dissociation and reassociation at neutral pH by a mild salt jump.  
 
4.4.1 DNA-labelled Humanized ferritin preparation  
 
The HumAfFt ferritin ability to encapsulate a large molecule such as a 
nucleic acid sequence was thus tested. However, due to the potential leak 
from the triangular pore, the DNA sequence should preferably be covalently 
bound to the internal ferritin cavity. Despite the apparent simple idea, various 
parameters concerning the linker should be considered, as the successful 
delivery and release rely on the choice of the molecule. Indeed the linker 
should be sufficiently stable to enable the conjugate to circulate in the 
bloodstream without premature release of the cargo which could potentially 
cause toxicity to normal tissues. On the other hand, the linker should also be 
cleavable at the target site where it should actively release the free drug. 
Among the most commonly employed linkers in this field, glutathione 
sensitive linkers have emerged for selective cargo release in the cytosol176. 
Indeed, any disulfide bond is generally stable in the blood stream while it is 
easily cleaved once inside the cell, due to the higher glutathione 
concentration in the cytosol43. The linker should therefore bear a disulfide 
moiety and, in order to selectively crosslink both the protein and the nucleic 
acid sequence, it must bear two additional reactive groups. The already 
available Cys54 in the HumAfFt inner cavity can be exploited as a unique 
site-selective attachment site, and a thiol moiety can be introduced at the end 
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of the DNA sequence for crosslinking. Thus, a sulfhydryl to sulfhydryl 
crosslinker containing a disulfide group will be needed. The commercially 
available DTME linker (Figure 44A) was chosen because of its disulfide 
cleavable bond and the two reactive maleimide moieties for the protein and 
DNA crosslinking. The similar BM(PEG)2 linker (Figure 44B), resistant to 
glutathione cleavage due to the absence of any disulfide moiety, was used as 
negative release control agent.  
 
 
A simple 22 base DNA sequence (Ro-DNA-SH), with no apparent active 
target or effect, was purchased from Sigma Aldrich and was modified with a 
thiol moiety at the 3’ end and a rhodamine fluorophore at the 5’ end to easily 
detect the molecule by UV-Vis and fluorescence spectroscopy.  
The crosslinking bioconjugation reaction between the three species, the 
ferritin, the linker and the DNA sequence, can take place according to two 
possible reaction sequences that must be tested and compared (Scheme 7).  
 
Figure 44: A) DTME cleavable bifunctional linker, B) BM(PEG)2 uncleavable bifunctional 
linker. The distance between the two reactive functional moieties are reported under the 
molecule in Å units  
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The first pathway envisaged a first reaction between the ferritin and the linker 
(Scheme 7-1A) and a second conjugation between the second reactive 
maleimide moiety of the linker and the thiol group on the DNA sequence 
(Scheme 7-1B). On the other hand, the linker could first be reacted with the 
DNA segment (Scheme 7-2A) and only later crosslinked to the ferritin Cys54 
(Scheme 7-2B). Both pathways were explored with the first pathway showing 
an increased reliability and higher yields, while the second reaction sequence 
presented several limitations due to the possible multiple reactions between 
the linker and the DNA. Indeed, even though the reagents were reacted in a 
1:1 molar ratio, both the mono- and double- labelled (i.e. DNA-linker-DNA) 
products could be produced, and a purification step to isolate the mono-
labelled conjugate would be difficult. On the contrary, in Scheme 7-1A a 
high molar ratio of linker (10 eq.) could be mixed with ferritin, and easily 
removed by gel filtration chromatography, yielding a high labelling 
percentage as confirmed by mass spectrometry analysis (Figure 45).  
Scheme 7: Ferritin-linker-DNA crosslinking reaction pathways A and B 
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As shown in Figure 45B’ and 45C’, however, an encountered inconvenient 
was the crosslinking between two cysteines at the ferritin dimer interface as 
the two residues are located at a 14 Å distance, unfortunately matching the 
linker length. Thus, the two maleimide groups at the linker extremes reacted 
with the two Cys54 on two adjacent monomers preferring a linker to cysteine 
ratio of 1:2 instead of the correct 1:1 that left the second maleimide moiety 
Figure 45: MALDI-TOF mass spectra of A) HumAfFt, B) DTME-labelled HumAfFt 
monomer, B’) DTME-labelled HumAfFt crosslinked dimer, C) BM(PEG)2-labelled HumAfFt 
monomer,  C’) BM(PEG)2-labelled HumAfFt crosslinked dimer 
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available for further DNA conjugation. Nonetheless, this side reaction was 
minimized by fast addition of a high amount of linker, as verified both by 
denaturing SDS-PAGE and MALDI-TOF mass spectrometry analysis, 
resulting in a small amount of crosslinked dimers (approximately 15 %). 
After the first reaction step was optimised, the reaction and purification 
conditions of the crosslinking between linker-labelled ferritin and Ro-DNA-
SH were adjusted. The highest labelling yields were reached by dissociating 
the protein into dimers before the reaction between the ferritin and the DNA 
fragment. In this way, the available maleimide of the linker was more 
exposed to the solvent and accessible to the DNA segment thus yielding 
higher labelling percentages. The best labelling yields achieved per 24-meric 
cage were 160 % (i.e. 1.6 molecules of DNA per ferritin 24-mer) employing 
the DTME linker and 22 % (i.e. 1 molecule of DNA every 5 ferritin 24-meric 
cage) using the BM(PEG)2 linker. All the yields were determined by UV-Vis 
spectroscopy by calculating the ratio between the rhodamine fluorophore 
concentration at 530 nm, corresponding to the DNA concentration, and the 
protein concentration at 280 nm. Mass analysis could not highlight the 
ferritin-DNA conjugate since only a small percentage of DNA was bound 
with respect to the ferritin monomeric unit detected by mass spectroscopy. 
Therefore only the main ferritin-linker peak was detected due to the fact that 
the DNA-ferritin conjugate was under the instrumental detection limit. 
However, and surprisingly, although the two linkers were very similar, the 
BM(PEG)2 linker afforded lower labelling yields than the DTME reaction 
and the origin of this curious discrepancy is still under investigation.  
A control reaction was performed by mixing the ferritin with N-methyl 
maleimide (NMM), a small linker incapable of further reaction with the DNA 
segment. Correctly, nonspecific DNA binding to the ferritin cavity was not 
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found in the control reaction demonstrating both the effectiveness of the 
purification procedure and the successful encapsulation in the previously 
described experiments. 
 
4.4.2 DNA-labelled Humanized ferritin cellular uptake 
 
Despite the still improvable labelling yields, preliminary cytofluorimetry 
tests on HeLa cells were nevertheless carried out, in collaboration with the 
Italian Institute of Technology, to verify the DNA ferritin-mediated 
internalization in living cells. The protein was thus first labelled on the 
external surface with a fluorescein fluorophore and later labelled on the 
internal cavity with the DNA fragment crosslinked with the DTME and 
BM(PEG)2 linkers. The ferritins were then internalised by HeLa cells 
according to the standard conditions and analysed by flow cytometry by 
using a control sample with plain cells not incubated with the protein. As 
shown in Figure 46, the percentage of FITC positive cells was high for both 
ferritins (99.7 % and 90.3 % for the ferritin crosslinked with DTME and 
BM(PEG)2 respectively), while it was different for the rhodamine positive 
cells (99.6 % and 50.3 % respectively) reflecting the minor labelling degree 
of the Ro-DNA-SH-BM(PEG)2-HumAfFt. These data show that DNA 
encapsulation did not alter the TfR1 mediated HumAfFt internalization into 
HeLa cells. 
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4.4.3 DNA encapsulation by electrostatic interaction 
 
Following these first encouraging results, a third linker called NAEM (Figure 
47), bearing an amine group which will be mostly protonated in physiological 
buffers, was also examined. This linker was chosen with the aim of 
introducing 24 additional positive charges within the ferritin internal cavity 
that might promote a non-covalent electrostatic interaction with the 
negatively charged nucleic acid sequence and thus promote the DNA uptake 
without the need of a covalent DNA labelling.  
Figure 46: DNA-HumAfFt complex internalization analysis by flow cytometry 
Figure 47: NAEM linker molecular structure 
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The reaction was carried out according to the reaction scheme used for the 
two covalent linkers and a 13.5 % labelling yield per ferritin 24mer was 
obtained. Overall, the NAEM yield was the lowest yield obtained, far from 
the high yield reached with the DTME linker but not too much lower than the 
BM(PEG)2 yield. Although the DTME and BM(PEG)2 covalent strategies 
were superior with respect to the NAEM linker, the small amount of 
entrapped DNA that was found suggests that the introduction of 24 positive 
charges into the inner ferritin cavity may actually favour the DNA uptake 
compared to the control. Thus, in the future, the introduction of a high 
number of positive charges within the protein cavity could enable the 
encapsulation of various negatively charged molecules stabilised by non-
covalent electrostatic interactions. 
 
4.4.4 Conclusion and future perspectives 
 
In conclusion, even though the BM(PEG)2 crosslinking and encapsulation 
reaction must still to be improved, the reaction employing the DTME linker 
allowed the encapsulation of 1.6 DNA molecules per HumAfFt ferritin in its 
24-meric cage assembly, shielding and transporting the DNA into HeLa cells 
by TfR1 mediated internalization. Further FACS and confocal microscopy 
experiments will be needed to verify the cleavage of the disulfide linker and 
the consequent DNA release. In the future, eventually, the transport of active 
nucleic acid sequences such as siRNAs could eventually be attempted to 
evaluate their potential effect. Indeed, the use of HumAfFt as a transfecting 
agent and as carrier of active nucleic acid fragments would represent a 
marked improvement with respect to the ferritin pH-induced encapsulation, 
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considerably expanding the potential biotechnological application of this 
proteic nanodevice.  
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5. CONCLUSIONS 
 
The work described in this thesis is focused on ferritins and their remarkable 
properties. In particular, archaea ferritin proteins and the novel chimeric 
humanized archaea ferritin HumAfFt were investigated in detail and their 
potential as nanoplatforms for the encapsulation and the targeted cellular 
delivery of drugs or diagnostic probes has been explored. The versatility of 
the ferritin cage allowed the insertion of various key modifications within the 
amino acid sequence, which had been further chemically functionalised for 
various applications, with the main objective to study ferritin self-assembly 
and encapsulation ability for the delivery of a wide variety of molecules.  
The protein matrix permeability and the diffusion of molecules through 
various archaea protein cages were investigated, highlighting an unexpected 
flexibility, even within apparently impermeable closed ferritin structures such 
as Pyrococcus fulgidus ferritin, and a facilitated entrance through the 
Archaeoglobus fulgidus ferritin (AfFt) which bears characteristic wide 
triangular pores. The possibility to encapsulate various molecules within the 
peculiar AfFt cage either by diffusion through the large openings or by 
assembly/disassembly entrapment in a physiological environment is of 
outstanding importance for biotechnological applications envisaging a mild 
cargo encapsulation strategy, alternative to the canonical procedure requiring 
drastic pH values. Thanks to a newly synthesised pyrene-ferritin conjugate 
the thermodynamic and kinetic aspects of the AfFt self-assembly were deeply 
characterised by observing the shifts in the pyrene excimer fluorescence 
emission upon protein oligomerization, which strongly reflected the protein 
assembly state. The magnesium- and the sodium- triggered assembly were 
compared, with the magnesium-induced process being superior in all aspects. 
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Indeed, magnesium cations were able to induce a faster cage closure at lower 
salt concentrations, thus potentially representing a marked improvement for 
the controlled encapsulation of molecules and a convenient alternative to the 
classical sodium-triggered self-assembly, which takes place on a 
considerably longer time scale. In addition, the extremely cooperative 
magnesium-induced process is also completely reverted by EDTA treatment, 
offering an easy means to control the entire oligomerization process.  
Archaea ferritins can not be recognised by the human ferritin receptor TfR1, 
a receptor which is found to be overexpressed in several cancerous cells. 
Thus, to investigate archaea ferritins in vitro, a humanized chimeric ferritin 
HumAfFt, which combined the AfFt structure and assembly properties with 
the human H-ferritin recognition motif for the TfR1 receptor, was designed 
and successfully purified in our laboratory with high yields. 
Both the oligomerization properties and the TfR1 mediated internalization of 
HumAfFt into human cancerous HeLa cells were investigated by conjugating 
the protein with a pyrene molecule and by exploiting pyrene excimer 
fluorescence emission. These experiments confirmed both the assembly 
properties comparable to AfFt ferritin and the active internalization into 
mammalian cells. In particular, as the pyrene excimer intense emission was 
observed in living cells by two-photon fluorescence confocal microscopy, the 
pyrene-HumAfFt conjugate could represent the first example of a set of novel 
TfR1-selective pyrene-ferritin probes for TPFM bioimaging, which could be 
further expanded by pyrene derivatization.  
In order to further explore the HumAfFt versatility and ability to specifically 
target the overexpressed TfR1 receptor in human cancerous cells, a set of 
novel conjugates were designed and employed for delivery of small nucleic 
acids, a technique nowadays widely employed in cancer treatment. A small 
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DNA sequence was covalently bound or physically entrapped within the 
internal cavity of the ferritin by mildly dissociating and reassociating the 
protein cage at neutral pH. The modified ferritin was able to stabilize the 
DNA sequence, shielding it from degradation and carrying it inside HeLa 
cells as confirmed by FACS analysis. These encouraging results, might 
widen the scope of HumAfFt as a transfecting agent and as a carrier of active 
nucleic acid sequences, considerably expanding the biotechnological 
application of this protein biotherapeutic nanodevice.  
Overall, the several experiments discussed in this thesis support the 
importance of ferritins as optimal and unique nanoparticles which, thanks to 
their widely explored versatility together with the TfR1 selective targeting, 
can transport a variety of molecules spanning from imaging probes to 
therapeutically active molecules for bioimaging and drug delivery 
applications.  
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